US4208511A - Isomorphic copolyoxalates and sutures thereof - Google Patents

Isomorphic copolyoxalates and sutures thereof Download PDF

Info

Publication number
US4208511A
US4208511A US05/915,500 US91550078A US4208511A US 4208511 A US4208511 A US 4208511A US 91550078 A US91550078 A US 91550078A US 4208511 A US4208511 A US 4208511A
Authority
US
United States
Prior art keywords
polymer
isomorphic
polymers
mol
filaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/915,500
Inventor
Shalaby W. Shalaby
Dennis D. Jamiolkowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethicon Inc
Original Assignee
Ethicon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/752,374 external-priority patent/US4141087A/en
Application filed by Ethicon Inc filed Critical Ethicon Inc
Priority to US05/915,500 priority Critical patent/US4208511A/en
Application granted granted Critical
Publication of US4208511A publication Critical patent/US4208511A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/12Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/16Dicarboxylic acids and dihydroxy compounds
    • C08G63/18Dicarboxylic acids and dihydroxy compounds the acids or hydroxy compounds containing carbocyclic rings
    • C08G63/199Acids or hydroxy compounds containing cycloaliphatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/06Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
    • A61B17/06114Packages or dispensers for needles or sutures
    • A61B17/06133Packages or dispensers for needles or sutures of parallelepipedal shape, e.g. made of rectangular or slightly oval panels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/06Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
    • A61B17/06166Sutures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/06At least partially resorbable materials
    • A61L17/10At least partially resorbable materials containing macromolecular materials
    • A61L17/105Polyesters not covered by A61L17/12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00004(bio)absorbable, (bio)resorbable, resorptive

Definitions

  • Absorbable suture materials have traditionally been natural collagenous materials obtained from sheep or beef intestine, commonly known as catgut. More recently, it has been proposed to manufacture synthetic absorbable sutures from polyesters of hydroxycarboxylic acids, notably polylactide, polyglycolide, and copolymers of lactide and glycolide. Such synthetic absorbable sutures are described in U.S. Pat. Nos. 3,636,956 3,297,033 and elsewhere in the literature. Polyesters of succinic acid have also been suggested for at least partially bioresorbable surgical articles as disclosed for example in U.S. Pat. No. 3,883,901.
  • an ideal absorbable suture should have good handling properties, should approximate and hold tissue for proper healing with minimal tearing and tissue damage, should have adequate straight tensile and knot strength, should be controllably uniform in properties including dimensional stability within the body, should be sterilizable, should be absorbable by living tissue, preferably at a constant rate regardless of the place in the body or the condition of the patient and without causing such unfavorable tissue reactions as walling off, granuloma formation or excessive edema, and finally should be capable of being properly and easily tied into surgical knots.
  • multifilament sutures manufactured from polymers of lactide and glycolide fulfill the above requirements to a large degree, monofilament sutures of these materials are considerably less flexible than catgut and these synthetic sutures are accordingly generally limited to a multifilament, braided construction.
  • Sutures of glycolide polymers are also not suitable for sterilization by radiation without suffering severe degradation of physical properties.
  • copolyoxalate copolymers having isomorphic sequences can be melt extruded into pliable, monofilament fibers which have good in vivo strength retention and are absorbed in animal tissue without significant adverse tissue reaction.
  • the fibers have good tensile and knot strength, and can be sterilized by gamma radiation without serious loss of these properties.
  • monofilament sutures of the polymers of the present invention have a high degree of softness and flexibility not found in many synthetic absorbable sutures of the prior art.
  • a further object of this invention is to provide synthetic absorbable sutures of isomorphic copolyoxalates. It is a yet further object of this invention to provide surgical aids and prostheses fabricated of fibers or cast or machined from blocks of isomorphic copolyoxalate polymers.
  • Highly crystalline isomorphic polyoxalate polymers are prepared by reacting mixtures of cyclic and linear diols with dialkyl oxalate, preferably in the presence of an inorganic or organometallic catalyst.
  • the diols comprising the reaction mixture have the same carbon chain length separation between terminal OH groups of 6 or 8 carbon atoms.
  • the cyclic diol may be trans 1,4-cyclohexane dialkanol or p-phenylene dialkanol and comprises from about 5 to 95 mol percent, and preferably from 40 to 75 mol percent of the total diol reactant.
  • Copolymers prepared by the transesterification reaction of the two diols and diethyl oxalate are melt extruded into highly crystalline filaments suitable for use as synthetic absorbable sutures.
  • Drawn and oriented filaments are characterized by high tensile and knot strength, a Young's modulus in most cases of less than about 600,000 psi providing a high order of filament softness and flexibility, and good strength retention and minimal tissue reaction in vivo.
  • Polymers of the present invention are comprised of isomorphic units of cyclic and linear oxalates and have the general formula ##STR1## wherein each R is ##STR2## with from about 5 to 95 mol percent, and preferably from about 40 to 75 mol percent of R groups being I; A is trans 1,4-cyclohexylene or p-phenylene, n is 1 or 2 and is the same for I and II, and x is the degree of polymerization resulting in a polymer having an inherent viscosity of at least 0.3 as determined on a solution of 1 gm of polymer in 1 liter of chloroform or hexafluoro-isopropanol at 25° C. Most preferably, the inherent viscosity of the polymer is at least about 0.5 and the polymer is fiber forming.
  • Polymers of the present invention are conveniently prepared by an ester interchange reaction between the aforedescribed mixture of diols and a lower ester of oxalic acid, preferably in the presence of an ester interchange catalyst.
  • the preferred ester of oxalic acid is diethyl oxalate.
  • the ester interchange is most preferably conducted in two stages wherein the reactants are first heated with stirring under a nitrogen atmosphere to form a prepolymer with the removal of ethanol, followed by postpolymerization under heat and reduced pressure to obtain a final polymer of the desired molecular weight and fiber forming quality.
  • Polymers with low or moderate degrees of polymerization are postpolymerized in the liquid state or as finely-divided solid particles, depending on their melting temperature range.
  • the polymer is melt extruded through a spinnerette in a conventional manner to form one or more filaments which are subsequently drawn about 4 ⁇ to 6 ⁇ in order to achieve molecular orientation and improve tensile properties.
  • the resulting oriented filaments have good tensile and dry knot strength and good in vivo strength retention.
  • the crystallinity and hence suitability for fiber-formation in both the AB and AA-BB type polyesters decreases significantly when the mol fraction of the major comonomer sequence decreases below about 80%.
  • the comonomer sequences are isomorphic, chains composed of slightly less than 80% of the major sequences can pack into a crystalline form.
  • randomly constructed copolyester chains based on almost equal amounts of the isomorphic comonomer sequences are generally found to be non-crystalline and poor fiber formers.
  • the isomorphic copolyesters of the present invention display an unexpectedly high level of crystallinity of about 45% in a 50/50 copolyester.
  • the polymers of the present invention are also unusual in that all copolymers through the entire composition range of from 5 to 95% of each isomorphic comonomer demonstrate levels of crystallinity comparable to those encountered in the parent homopolymers; namely between 30 and 50% depending on the thermal history.
  • a similarly striking observation characteristic of these copolyesters is their display of melting endotherms, as shown by DSC, for the crystalline regions of all copolymers within the composition range of from about 5 and 95 mol % of each isomorphic comonomer. Constructed curves of the melting temperature versus composition did not reveal any positive eutectic composition in these systems.
  • the X-ray and DSC data suggest strongly the uncommon presence of almost complete isomorphism in the copolyesters of the present invention.
  • Dimensional stability and tensile strength retention of the oriented filaments may be enhanced by subjecting the filaments to an annealing treatment.
  • This optional treatment consists of heating the drawn filaments to a temperature of from about 40° to 130° C., most preferably from about 60° to 110° C. while restraining the filaments to prevent any substantial shrinkage.
  • the filaments are held at the annealing temperature for a few seconds to several days or longer depending on the temperature and processing conditions. In general, annealing at 60° to 110° C. for up to about 24 hours is satisfactory for the polymers of the present invention.
  • Optimum annealing time and temperature for maximum fiber in vivo strength retention and dimensional stability is readily determined by simple experimentation for each fiber composition.
  • Filaments of the present invention may be used as sutures in either a monofilament or a multifilament construction.
  • Multifilament sutures are preferably braided but may also be twisted or covered in accordance with common practice.
  • Sutures prepared from oriented filaments of the present invention are characterized by a straight tensile strength of at least about 30,000 psi and a knot strength of at least about 20,000 psi, although significantly higher strengths may be obtained.
  • a DuPont 990 DSC apparatus were used to record the glass transition (T g ), crystallization (T c ) and melting (T m ) temperatures of the polymers under nitrogen, using about 5 mg samples and a heating rate of 10° C./min or as otherwise specified.
  • the thermogravimetric analysis (TGA) data of the polymers were recorded under nitrogen using a DuPont 950 TGA apparatus and a heating rate of 10° or 20° C./min with about 10 mg samples.
  • a Phillips vertical goniometer with graphite crystal monochromatized copper K.sub. ⁇ radiation was used to obtain the X-ray powder and fiber diffraction patterns of the polymers. Crystallinity was determined by the method of Hermans and Weidinger and the diffractometer patterns were resolved with a DuPont 310 curve analyzer.
  • In vivo absorption was determined by implanting two 2 cm segments of monofilament fiber into the left gluteal muscles of female Long Evans rats. The implant sites were recovered after periods of 60, 90, 120 and 180 days and examinated microscopically to determine the extent of absorption.
  • In vivo absorption (subcutaneous) is a non-histological technique in which continuous observation of the biological degradation of segments of suture is made by implanting two segments of suture, 2 cm long, into the abdominal subcutis of young female rats. The implants are readily visible when the skin is wetted with propylene glycol and extent of absorption can be determined by subjective visual examination.
  • In vivo strength retention was determined by implanting segments of sutures in the posterior dorsal subcutis of female Long Evans rats for period of 5 to 30 days. The sutures were recovered at the designated periods and pull-tested for straight tensile strength.
  • In vitro strength retention was determined by placing segments of sutures in the afore-defined buffer at 50° C. for periods of 2 to 4 days. The sutures were recovered at the designated periods and pull-tested for straight tensile strength.
  • Diethyl oxalate was heated with selected diols in a mechanically-stirred reactor using a stannous alkanoate or organic titanate catalyst. The reaction was conducted under a nitrogen atmosphere at suitable temperatures until a substantial portion of the calculated amount of ethanol was obtained. Postpolymerization of the resulting prepolymer was then continued under reduced pressure using a suitable heating scheme. At the end of the postpolymerization period, the molten polymer was allowed to cool slowly at room temperature, isolated, ground and dried at 25° C. to 80° C. (depending on the polymer T m ) in vacuo for at least one day.
  • the prepolymer can be postpolymerized partially in the liquid state, cooled, and then postpolymerized further in the solid state as finely divided particles.
  • Detailed experimental conditions for the preparation of representative samples of isomorphic polyoxalates and important properties of the resulting polymers are presented below.
  • Distilled diethyl oxalate (19.0 g, 0.130 mol), recrystallized trans 1,4-cyclohexanedimethanol (19.8 g, 0.137 mol), 1,6-hexadiol (0.856 g, 0.00724 mol) and stannous octoate (0.33 M in toluene; 0.080 ml, 0.026 mmol) were added under dry and oxygen-free conditions to a glass reactor equipped for magnetic stirring.
  • the prepolymer was formed by heating the mixture at 120° C. for 3 hours under nitrogen at 1 atmosphere while allowing the formed ethanol to distill, followed by heating at 160° C. for 2 hours.
  • the prepolymer was then heated in vacuo (0.05 mm Hg) at 220° C. for 1 hour, and the postpolymerization completed by heating at 215° C. for an additional 6 hours.
  • the polymer was then allowed to cool to room temperature, isolated and ground, and finally dried in vacuo at room temperature.
  • Polymer Melt-Spinning The polymer was spun using an Instron Rheometer with a 30 mil die at 207° C.
  • Distilled diethyl oxalate (58.4 g, 0.400 mols), recrystallized trans 1,4-cyclohexanedimethanol (less than 1% cis isomer; 53.9 g, 0.374 mols), 1,6-hexanediol (7.8 g, 0.066 mol), and stannous octoate (0.33 M in toluene; 0.40 ml, 0.13 mmol) were added under dry and oxygen-free conditions to a glass reactor equipped for mechanical stirring. The mixture was heated at 120° and 150° C. for 2 and 3 hours, respectively, under nitrogen at one atmosphere while the formed ethanol distilled.
  • the prepolymer was allowed to cool, then reheated to 200° C. under reduced pressure (0.1 mm Hg). Temperatures of 200°, 220° and 230° C. were maintained for 2, 3 and 4 hours while the collection of distillates continued.
  • Polymer Melt-Spinning The polymer was spun at 230° C. using an Instron Rheometer with a 40 mil die. The fiber was quenched in ice water, wound, dried and subsequently drawn.
  • the prepolymer was formed by heating the mixture at 120° C. for 2 hours under nitrogen at 1 atmospheere while allowing the formed ethanol to distill, followed by 160° C. for 2.5 hours.
  • the mixture was allowed to cool, then reheated in vacuo (0.1 mm Hg) to 140° C. and maintained until the prepolymer melted. The temperature was then increased to 190° C., maintained for 30 minutes, then raised to 200° C. for 1.5 hours.
  • the melt post-polymerization of the stirred polymer was completed by heating at 220° C. for 4.5 hours.
  • Polymer Melt-Spinning The polymer was spun at 240° C. using an Instron Rheometer equipped with a 40 mil die. The extruded filaments were quenched in ice water, wound, then dried at room temperature in vacuo, and subsequently drawn 4 ⁇ .
  • the temperature was then increased and maintained at 180° C., 190° C. and 200° C. for 2, 5 and 2 hours, respectively, while removing excess and formed diols.
  • the polymer was allowed to cool, isolated, ground, and dried in vacuo at room temperature.
  • Polymer Melt-Spinning The polymer was spun using an Instron Rheometer with a 30 mil die at 172° C. The extruded filaments were quenched in ice water, dried in vacuo at room temperature, and finally drawn 5 ⁇ at 43° C.
  • the prepolymer was cooled, then reheated in vacuo (0.03 mm Hg) and maintained at 80, 120, 150, 170 and 180° C. for 1, 2, 2, 3 and 1.5 hours, respectively.
  • the postpolymerization of the polymer melt was completed by heating at 195° C. for 6 hours while continuing to stir and remove distillates.
  • the polymer was cooled, isolated, ground, and then dried at room temperature.
  • Polymer Melt Spinning The polymer was spun at 175° C. using an Instron Rheometer with a 30 mil die. The resulting fibers were subsequently drawn 4l ⁇ at 50° C.
  • Tissue Reaction Two centimeter long samples of sterilized (by ⁇ -radiation, 2.5 Mrads) drawn fiber were implanted subcutaneously in the abdominal wall of young female Long Evans strain rats. At intervals of 3, 14, 28, 56 and 90 days, two rats were sacrificed for examination of implants. The skin containing the fibers was excised and affixed to plastic sheets for preservation in formalin. Two tissue blocks were cut transversely from each site and embedded in paraffin for histologic preparation. Eight strained samples were examined at each interval for tissue reaction to the fibers. Only mild foreign body reactions were detected.
  • Fiber segments sterilized by ⁇ -radiation (2.5 Mrads) approximately 2 cm in length were inserted into the ventral abdominal subcutis of Long Evans rats (100 g, female) to determine the rate of absorption of the drawn fibers.
  • One to two rats were sacrified after various periods after implantation.
  • the skin containing the implant sites was removed and dried.
  • These preparations were examined and evaluated using both dissecting and transmission microscopes. Estimates of the amount of implant remaining were based on the length of the segment or fragments remaining and the decrease in the surface area made by palpating the implant in the dried hide and comparing it with a one week old preparation. Implants were fragmented at one week; migration and clumping of fragments was noted at subsequent kill periods.
  • Distilled diethyl oxalate (38.0 g, 0.260 mol), recrystallized trans 1,4-cyclohexanedimethanol (20.2 g, 0.140 mol), 1,6-hexanediol (16.5 g, 0.140 mol), and stannous octoate (0.33 M in toluene, 0.16 ml, 0.053 mmol) were added under dry and oxygen-free conditions to a mechanically stirred glass reactor. Under nitrogen at one atmosphere, the mixture was heated to and maintained at 120° C. for 20 hours, while allowing the formed ethanol to distill.
  • the prepolymer was cooled and then reheated in vacuo (0.05 mm Hg) to and maintained at 80°, 120°, 140°, 165°, 175°, 185°, and 195° C. for 1, 1, 3, 3.5, 2, 1 and 1 hour respectively.
  • the removal of the diols was continued by heating at 200° C. for 8 hours to complete the postpolymerization.
  • the polymer was cooled, isolated, ground, and then dried in vacuo at room temperature.
  • Polymer Melt Spinning The polymer was spun at 136° C. using an Instron Rheometer (40 mil die) and was immediately drawn 5 ⁇ at 53° C.
  • X-ray Data Major reflections correspond to 8.9 (W), 4.84 (M), 4.41 (S), and 5.40 A (W) d-spacings; 36% crystallinity.
  • the implants were fragmented, clumping, and migrating, with the bulk of the suture being absorbed between 6 to 11 weeks. Thereafter, fragments with scattered birefringent particles or birefringent particles in a shelllike outline were observed. The birefringent particles decreased in amount until at 36 weeks only a few widely scattered particles were noted.
  • the prepolymer was cooled and then reheated in vacuo (0.05 mm Hg) and maintained at 170°, 190° and 205° C. for 3, 2.5 and 3 hours respectively while continuing to remove excess and formed diol to complete the postpolymerization.
  • the polymer was cooled, isolated, ground, and then dried in vacuo at room temperature.
  • Polymer Melt Spinning The polymer was spun at 150° C. using an Instron Rheometer (40 mil die) and was drawn 4X at 50° C. followed by 1.5X at 72° C.
  • X-ray Data Major reflections correspond to 9.11 (MS), 4.82 (S), 4.60 (W), 4.37 (S) and 3.45 A (W) d-spacings; 46% crystallinity.
  • Distilled diethyl oxalate (36.5 g, 0.250 mol), recrystallized trans 1,4-cyclohexanedimethanol (11.5 g, 0.0797 mol), 1,6 hexanediol (22.4 g, 0.190 mol), and stannous octoate (0.33 M in toluene; 0.16 ml, 0.053 mmol) were added under dry and oxygen-free conditions to a mechanically stirred reactor. The mixture was heated to and maintained at 125, 140 and 160° C. for 2, 2 and 1 hour, respectively, under nitrogen at one atmosphere while allowing the formed ethanol to distill.
  • the prepolymer was cooled and then reheated in vacuo (0.1 mm Hg) and maintained at 150° and 185° C. for 16 and 3 hours, respectively.
  • the postpolymerization was completed by maintaining the polymer at 200° C. for 5.5 hours while continuing to remove the diols under vacuum.
  • the polymer was then cooled, isolated, ground and dried in vacuo at room temperature.
  • Polymer Melt Spinning The polymer was spun at 125° C. using an Instron Rheometer with a 40 mil die. The fiber was quenched in ice water, wound, dried in vacuo at room temperature, and subsequently drawn 5.6X at room temperature, followed by annealing at 55° C.
  • Fiber Properties Diameter 8.3 mils, straight tensile strength 5.18 ⁇ 10 4 psi, knot tensile strength 3.51 ⁇ 10 4 psi, modulus 2.11 ⁇ 10 5 and elongation 50%.
  • the fibers had a median value of 2 percent suture cross sectional area remaining (with a range of 0 to 20 percent).
  • Distilled diethyl oxalate (19.0 g, 0.130 mol), recrystallized trans 1,4-cyclohexanedimethanol (1.0 g, 0.0069 mol), 1,6-hexanediol (16.3 g, 0.138 mol), and stannous octoate (0.33 M in toluene; 0.08 ml, 0.026 mmol) were added under dry and oxygen-free conditions to a glass reactor equipped for magnetic stirring.
  • the prepolymer was formed by heating the mixture at 120° C. for 3 hours under nitrogen at one atmosphere while allowing the formed ethanol to distill, followed by 160° C. for 2 hours.
  • the prepolymer was heated and maintained at 205° C. for 8 hours in vacuo (0.05 mm Hg). The polymer was then cooled, isolated, ground, and dried at room temperature.
  • Polymer Melt Spinning The polymer was spun in an Instron Rheometer using 30 mil die at 85° C. The fibers were quenched in ice water and subsequently drawn 5X at room temperature.
  • Polymer Melt Spinning The polymer was spun at 166° C. using an Instron Rheometer equipped with a 30 mil die.

Abstract

Synthetic absorbable sutures are prepared from copolyoxalate polymers having isomorphic sequences. The polymers are derived from mixtures of cyclic and linear diols, each having the same carbon chain length of 6 or 8 atoms. The cyclic diol may be aliphatic or aromatic. The diols are polymerized with dialkyl oxalate, preferably in the presence of an inorganic or organometallic catalyst, to obtain a highly crystalline isomorphic copolyoxalate polymer which is melt extruded and drawn to form oriented filaments. The filaments are characterized by good initial tensile and knot strength and a high order of softness and flexibility. When implanted in living animal tissue, the fibers have good strength retention over a period of at least 21 days and eventually absorb with a minimal degree of adverse tissue reaction.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This is a continuation-in-part of application Ser. No. 752,374, filed Jan. 19, 1977.
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to synthetic absorbable sutures, and more particularly, to synthetic absorbable sutures comprising extruded and oriented filaments of copolymers of polyoxalates having isomorphic sequences.
2. Description of Prior Art
Absorbable suture materials have traditionally been natural collagenous materials obtained from sheep or beef intestine, commonly known as catgut. More recently, it has been proposed to manufacture synthetic absorbable sutures from polyesters of hydroxycarboxylic acids, notably polylactide, polyglycolide, and copolymers of lactide and glycolide. Such synthetic absorbable sutures are described in U.S. Pat. Nos. 3,636,956 3,297,033 and elsewhere in the literature. Polyesters of succinic acid have also been suggested for at least partially bioresorbable surgical articles as disclosed for example in U.S. Pat. No. 3,883,901.
Among the requirements of an ideal absorbable suture are that it should have good handling properties, should approximate and hold tissue for proper healing with minimal tearing and tissue damage, should have adequate straight tensile and knot strength, should be controllably uniform in properties including dimensional stability within the body, should be sterilizable, should be absorbable by living tissue, preferably at a constant rate regardless of the place in the body or the condition of the patient and without causing such unfavorable tissue reactions as walling off, granuloma formation or excessive edema, and finally should be capable of being properly and easily tied into surgical knots.
While multifilament sutures manufactured from polymers of lactide and glycolide fulfill the above requirements to a large degree, monofilament sutures of these materials are considerably less flexible than catgut and these synthetic sutures are accordingly generally limited to a multifilament, braided construction. Sutures of glycolide polymers are also not suitable for sterilization by radiation without suffering severe degradation of physical properties.
We have discovered that copolyoxalate copolymers having isomorphic sequences can be melt extruded into pliable, monofilament fibers which have good in vivo strength retention and are absorbed in animal tissue without significant adverse tissue reaction. The fibers have good tensile and knot strength, and can be sterilized by gamma radiation without serious loss of these properties. In addition, monofilament sutures of the polymers of the present invention have a high degree of softness and flexibility not found in many synthetic absorbable sutures of the prior art.
The preparation of polyoxalate polymers is described in the art. Carothers et al, J. Amer. Chem. Soc. 52, 3292 (1930) for example, describes the ester interchange reaction of diols such as ethylene glycol, 1,3-propanediol, or 1,4-butanediol with diethyl oxalate to yield a mixture of monomer, soluble polymer and insoluble polymer. The reaction of oxalic acid and an alkylene glycol to form polyester resins is described in U.S. Pat. No. 2,111,762, while the preparation of polyesters of fiber-forming quality from dicarboxylic acids and diols is described in U.S. Pat. No. 2,071,250-1 and 2,952,652. Isomorphic polymers including polyester copolymers have been discussed in the literature.sup.(1). The particular isomorphic copolyoxalates of the present invention however, have not previously been known, nor has their preparation or use as synthetic absorbable sutures been suggested heretofore.
It is accordingly an object of the present invention to provide new and useful polymers of isomorphic copolyoxalates and articles made therefrom. A further object of this invention is to provide synthetic absorbable sutures of isomorphic copolyoxalates. It is a yet further object of this invention to provide surgical aids and prostheses fabricated of fibers or cast or machined from blocks of isomorphic copolyoxalate polymers.
SUMMARY
Highly crystalline isomorphic polyoxalate polymers are prepared by reacting mixtures of cyclic and linear diols with dialkyl oxalate, preferably in the presence of an inorganic or organometallic catalyst. The diols comprising the reaction mixture have the same carbon chain length separation between terminal OH groups of 6 or 8 carbon atoms. The cyclic diol may be trans 1,4-cyclohexane dialkanol or p-phenylene dialkanol and comprises from about 5 to 95 mol percent, and preferably from 40 to 75 mol percent of the total diol reactant.
Copolymers prepared by the transesterification reaction of the two diols and diethyl oxalate are melt extruded into highly crystalline filaments suitable for use as synthetic absorbable sutures. Drawn and oriented filaments are characterized by high tensile and knot strength, a Young's modulus in most cases of less than about 600,000 psi providing a high order of filament softness and flexibility, and good strength retention and minimal tissue reaction in vivo.
DESCRIPTION OF PREFERRED EMBODIMENTS
Polymers of the present invention are comprised of isomorphic units of cyclic and linear oxalates and have the general formula ##STR1## wherein each R is ##STR2## with from about 5 to 95 mol percent, and preferably from about 40 to 75 mol percent of R groups being I; A is trans 1,4-cyclohexylene or p-phenylene, n is 1 or 2 and is the same for I and II, and x is the degree of polymerization resulting in a polymer having an inherent viscosity of at least 0.3 as determined on a solution of 1 gm of polymer in 1 liter of chloroform or hexafluoro-isopropanol at 25° C. Most preferably, the inherent viscosity of the polymer is at least about 0.5 and the polymer is fiber forming.
Polymers of the present invention are conveniently prepared by an ester interchange reaction between the aforedescribed mixture of diols and a lower ester of oxalic acid, preferably in the presence of an ester interchange catalyst. The preferred ester of oxalic acid is diethyl oxalate. The ester interchange is most preferably conducted in two stages wherein the reactants are first heated with stirring under a nitrogen atmosphere to form a prepolymer with the removal of ethanol, followed by postpolymerization under heat and reduced pressure to obtain a final polymer of the desired molecular weight and fiber forming quality. Polymers with low or moderate degrees of polymerization are postpolymerized in the liquid state or as finely-divided solid particles, depending on their melting temperature range.
The polymer is melt extruded through a spinnerette in a conventional manner to form one or more filaments which are subsequently drawn about 4× to 6× in order to achieve molecular orientation and improve tensile properties. The resulting oriented filaments have good tensile and dry knot strength and good in vivo strength retention.
It is well documented that the crystallinity and hence suitability for fiber-formation in both the AB and AA-BB type polyesters decreases significantly when the mol fraction of the major comonomer sequence decreases below about 80%. In some instances, if the comonomer sequences are isomorphic, chains composed of slightly less than 80% of the major sequences can pack into a crystalline form. However, randomly constructed copolyester chains based on almost equal amounts of the isomorphic comonomer sequences are generally found to be non-crystalline and poor fiber formers. Contrary to this general rule, the isomorphic copolyesters of the present invention display an unexpectedly high level of crystallinity of about 45% in a 50/50 copolyester. The polymers of the present invention are also unusual in that all copolymers through the entire composition range of from 5 to 95% of each isomorphic comonomer demonstrate levels of crystallinity comparable to those encountered in the parent homopolymers; namely between 30 and 50% depending on the thermal history. A similarly striking observation characteristic of these copolyesters is their display of melting endotherms, as shown by DSC, for the crystalline regions of all copolymers within the composition range of from about 5 and 95 mol % of each isomorphic comonomer. Constructed curves of the melting temperature versus composition did not reveal any positive eutectic composition in these systems. The X-ray and DSC data suggest strongly the uncommon presence of almost complete isomorphism in the copolyesters of the present invention.
Dimensional stability and tensile strength retention of the oriented filaments may be enhanced by subjecting the filaments to an annealing treatment. This optional treatment consists of heating the drawn filaments to a temperature of from about 40° to 130° C., most preferably from about 60° to 110° C. while restraining the filaments to prevent any substantial shrinkage. The filaments are held at the annealing temperature for a few seconds to several days or longer depending on the temperature and processing conditions. In general, annealing at 60° to 110° C. for up to about 24 hours is satisfactory for the polymers of the present invention. Optimum annealing time and temperature for maximum fiber in vivo strength retention and dimensional stability is readily determined by simple experimentation for each fiber composition.
Filaments of the present invention may be used as sutures in either a monofilament or a multifilament construction. Multifilament sutures are preferably braided but may also be twisted or covered in accordance with common practice. For use as sutures, it is necessary that the fibers be sterile, and sterilization may be accomplished by exposing the fibers to Cobalt 60 gamma radiation or to ethylene oxide. Such sterilization technique are well known and commonly practiced in suture manufacture.
Since the function of a suture is to join and hold severed tissue until healing is well along, and to prevent wound separation as a result of movement of exercise, a suture must meet certain minimum standards of strength. It is particularly important that strength be maintained when knots are tied and during the actual procedure of drawing tight a suitable knot. Sutures prepared from oriented filaments of the present invention are characterized by a straight tensile strength of at least about 30,000 psi and a knot strength of at least about 20,000 psi, although significantly higher strengths may be obtained.
The preparation of high molecular weight oriented filaments of isomorphic polyoxalates is further illustrated by the following examples where all percentages are on a molar basis unless otherwise noted. The following analytical methods were used to obtain the data reported in the examples. Inherent viscosity (ηinh) was obtained on polymer solutions (1 gram/liter) in chloroform or hexafluoro-isopropanol (HFIP) at 25° C. The infrared spectra of polymer films (cast from CHCl3 or HFIP) were recorded on a Beckman Acculab 1 spectrophotometer. The NMR spectra of the polymer solutions in CDCl3 were recorded on an MH-100 or CFT-20 spectrophotometer. A DuPont 990 DSC apparatus were used to record the glass transition (Tg), crystallization (Tc) and melting (Tm) temperatures of the polymers under nitrogen, using about 5 mg samples and a heating rate of 10° C./min or as otherwise specified. The thermogravimetric analysis (TGA) data of the polymers were recorded under nitrogen using a DuPont 950 TGA apparatus and a heating rate of 10° or 20° C./min with about 10 mg samples. A Phillips vertical goniometer with graphite crystal monochromatized copper K.sub.α radiation was used to obtain the X-ray powder and fiber diffraction patterns of the polymers. Crystallinity was determined by the method of Hermans and Weidinger and the diffractometer patterns were resolved with a DuPont 310 curve analyzer.
In vitro hydrolysis of polymer discs (about 1.2 g, 2.2 cm diameter) and monofilaments (7-25 mil) was conducted at 37° C. in phosphate buffer comprising a solution of 27.6 g sodium dihydrogenphosphate monohydrate in 1000 ml water adjusted to pH 7.25 with sodium hydroxide.
In vivo absorption (muscle) was determined by implanting two 2 cm segments of monofilament fiber into the left gluteal muscles of female Long Evans rats. The implant sites were recovered after periods of 60, 90, 120 and 180 days and examinated microscopically to determine the extent of absorption. In vivo absorption (subcutaneous) is a non-histological technique in which continuous observation of the biological degradation of segments of suture is made by implanting two segments of suture, 2 cm long, into the abdominal subcutis of young female rats. The implants are readily visible when the skin is wetted with propylene glycol and extent of absorption can be determined by subjective visual examination.
In vivo strength retention was determined by implanting segments of sutures in the posterior dorsal subcutis of female Long Evans rats for period of 5 to 30 days. The sutures were recovered at the designated periods and pull-tested for straight tensile strength.
In vitro strength retention was determined by placing segments of sutures in the afore-defined buffer at 50° C. for periods of 2 to 4 days. The sutures were recovered at the designated periods and pull-tested for straight tensile strength.
EXAMPLES General Polymerization Procedure
Diethyl oxalate was heated with selected diols in a mechanically-stirred reactor using a stannous alkanoate or organic titanate catalyst. The reaction was conducted under a nitrogen atmosphere at suitable temperatures until a substantial portion of the calculated amount of ethanol was obtained. Postpolymerization of the resulting prepolymer was then continued under reduced pressure using a suitable heating scheme. At the end of the postpolymerization period, the molten polymer was allowed to cool slowly at room temperature, isolated, ground and dried at 25° C. to 80° C. (depending on the polymer Tm) in vacuo for at least one day. Alternatively, the prepolymer can be postpolymerized partially in the liquid state, cooled, and then postpolymerized further in the solid state as finely divided particles. Detailed experimental conditions for the preparation of representative samples of isomorphic polyoxalates and important properties of the resulting polymers are presented below.
EXAMPLE I 95/5 Poly (trans 1,4-Cyclohexylenedicarbinyl-co-hexamethylene Oxalate)
Distilled diethyl oxalate (19.0 g, 0.130 mol), recrystallized trans 1,4-cyclohexanedimethanol (19.8 g, 0.137 mol), 1,6-hexadiol (0.856 g, 0.00724 mol) and stannous octoate (0.33 M in toluene; 0.080 ml, 0.026 mmol) were added under dry and oxygen-free conditions to a glass reactor equipped for magnetic stirring. The prepolymer was formed by heating the mixture at 120° C. for 3 hours under nitrogen at 1 atmosphere while allowing the formed ethanol to distill, followed by heating at 160° C. for 2 hours. The prepolymer was then heated in vacuo (0.05 mm Hg) at 220° C. for 1 hour, and the postpolymerization completed by heating at 215° C. for an additional 6 hours. The polymer was then allowed to cool to room temperature, isolated and ground, and finally dried in vacuo at room temperature.
Polymer Characterization: ηinh in CHCl3 =0.05. DSC (20° C./min.): Tm =210° C.
Polymer Melt-Spinning: The polymer was spun using an Instron Rheometer with a 30 mil die at 207° C.
In Vitro Evaluation: The undrawn fibers lost 21 and 66 percent of their initial mass after immersion in phosphate buffer at 37° C. for 42 and 127 days, respectively.
EXAMPLE II 85/15 Poly (1,4-Cyclohexylenedicarbinyl-co-hexamethylene Oxalate)
Distilled diethyl oxalate (58.4 g, 0.400 mols), recrystallized trans 1,4-cyclohexanedimethanol (less than 1% cis isomer; 53.9 g, 0.374 mols), 1,6-hexanediol (7.8 g, 0.066 mol), and stannous octoate (0.33 M in toluene; 0.40 ml, 0.13 mmol) were added under dry and oxygen-free conditions to a glass reactor equipped for mechanical stirring. The mixture was heated at 120° and 150° C. for 2 and 3 hours, respectively, under nitrogen at one atmosphere while the formed ethanol distilled. The prepolymer was allowed to cool, then reheated to 200° C. under reduced pressure (0.1 mm Hg). Temperatures of 200°, 220° and 230° C. were maintained for 2, 3 and 4 hours while the collection of distillates continued. The resulting polymer (ηinh in CHCl3 =0.49) was cooled, isolated, ground (2 mm screen size), and then dried in vacuo at room temperature. Portions (30 g) of this ground polymer were postpolymerized in the solid state in glass reactors equipped for magnetic stirring by heating in vacuo (0.1 mm Hg) at 185° C. for 22 hours.
Polymer-Characteristization: ηinh in CHCl3 =1.14. DSC (20° C./min.): Tm =187° C.
Polymer Melt-Spinning: The polymer was spun at 230° C. using an Instron Rheometer with a 40 mil die. The fiber was quenched in ice water, wound, dried and subsequently drawn.
Fiber Properties: Fibers drawn 5X in two stages, 4X at 62° C. followed by 1.25X at 119° C. exhibited the following properties: diameter=8.5 mils, straight tensile strength=8.39×104 psi; knot tensile strength=5.06×104 psi; modulus=6.61×105 psi; elongation=15%.
In Vivo Evaluation: Sterilized (via γ-radiation, 2.5 Mrads), drawn monofilament (8.5 mils) retained 89, 75, 10 and zero percent of its initial breaking strength (4.8 lbs.) after subcutaneous implantation in rat muscle for 3, 7, 14 and 21 days respectively. Drawn filaments implanted into the gluteal muscles of rats elicited median tissue responses in the slight range throughout a 180 day post-implanation period. Filaments drawn 4× at 60° C. followed by 1.25× at 110° C. and having a straight tensile of 6.76×104 psi showed indications of initial degradation 20 to 26 weeks after implantation.
In Vitro Evaluation: Fibers drawn 4× at 60° C. (exhibiting a straight tensile of 4.33×104 psi) lost 40 percent of their initial mass after immersion in phosphate buffer at 37° C. for 84 days.
EXAMPLE III 80/20 Poly (1,4-Cyclohexylenedicarbinyl-cohexamethylene Oxalate)
Distilled diethyl oxalate (43.8 g, 0.300 mol), recrystallized trans 1,4-cyclohexanedimethanol (cis isomer content=1.0%, 36.3 g, 0.252 mol), 1.6-hexanediol (7.4 g, 0.063 mol), and stannous oxalate (12.4 mg., 0.060 mmol) were added under dry and oxygen-free conditions to a glass reactor equipped for mechanical stirring. The prepolymer was formed by heating the mixture at 120° C. for 2 hours under nitrogen at 1 atmospheere while allowing the formed ethanol to distill, followed by 160° C. for 2.5 hours. The mixture was allowed to cool, then reheated in vacuo (0.1 mm Hg) to 140° C. and maintained until the prepolymer melted. The temperature was then increased to 190° C., maintained for 30 minutes, then raised to 200° C. for 1.5 hours. The melt post-polymerization of the stirred polymer was completed by heating at 220° C. for 4.5 hours. The polymer was cooled, isolated, ground (screen size=2 mm) and dried in vacuo at room temperature. To obtain the final product, the ground polymer was post-polymerized in the solid state in a glass reactor equipped for magnetic stirring by heating at 180° C. in vacuo (0.05 mm Hg) for 24 hours while allowing the formed diols to distill.
Polymer Characterization: ηinh in CHCl3 =1.33. DSC (20° C./min.): Tm =205° C.
Polymer Melt-Spinning: The polymer was spun at 240° C. using an Instron Rheometer equipped with a 40 mil die. The extruded filaments were quenched in ice water, wound, then dried at room temperature in vacuo, and subsequently drawn 4×.
Fiber Properties: Diameter=9.0 mils; straight tensile strength=7.31×104 psi; knot tensile strength=3.46×104 psi; modulus=7.7×105 psi; elongation=15%.
In Vivo Evaluation: Sterilized (by γ-radiation, 2.5 Mrads), fibers (9.0 mil) retained 85, 20 and zero percent of their initial breaking strength (4.2 lbs.) after subcutaneous implantation in rat muscles for 3, 7 and 14 days, respectively. These fibers were also implanted into the gluteal muscles of rats to determine tissue response and absorption characteristics. The median tissue response elicited by the samples was in the slight range after 5 days post implantation and in the minimal range after 42 days; absorption of the samples was first noted at 120 days and by 180 days approximately fifty percent of the material had been absorbed.
EXAMPLE IV 80/20 Poly (1,4-Cyclohexylenedicarbinyl-cohexamethylene Oxalate)
Distilled diethyl oxalate (23.4 g, 0.160 mol), recrystallized trans 1,4-cyclohexanedimethanol (cis isomer content=6.3%; 20.0 g, 0.139 mol), 1,6-hexanediol (4.1 g, 0.035 mol) and Tyzor OG* (0.117 M in toluene, 0.28 ml, 0.033 mmols) were added under dry and oxygen-free conditions to a glass reactor equipped for magnetic stirring. A prepolymer was formed by heating the mixture at 120° C. for 19 hours under nitrogen at 1 atmosphere while allowing the formed ethanol to distill. The pressure was then reduced (0.05 mm Hg) and heating at 120° C. continued for 30 minutes longer. The temperature was then increased and maintained at 180° C., 190° C. and 200° C. for 2, 5 and 2 hours, respectively, while removing excess and formed diols. The polymer was allowed to cool, isolated, ground, and dried in vacuo at room temperature.
Polymer Characterization: ηinh in CHCl3 =0.46. DSC (10° C./min.): Tm =171° C. TGA (10° C./min. under N2): 0.25% weight lost at 275° C.
Polymer Melt-Spinning: The polymer was spun using an Instron Rheometer with a 30 mil die at 172° C. The extruded filaments were quenched in ice water, dried in vacuo at room temperature, and finally drawn 5× at 43° C.
Fiber Properties: ηinh in CHCl3 =0.42.
X-ray: Major reflections correspond to 8.9 (W), 4.84 (M), 4.41 (S) and 3.42 A (W) d-spacings; 26% crystallinity. (Undrawn filaments were found to be 22% crystalline which increased to 31% by annealing at 70° C. for one hour).
Physical Properties: Diameter=11.1 mils; straight tensile strength=2.07×104 psi; elongation=35%.
In Vivo Evaluation: The rate of absorption and tissue response of drawn filaments was determined by implantation into the ventral abdominal subcutis of Long-Evans rats. Some evidence of filament degradation was noted 11 to 14 weeks after implantation, with the bulk of the fiber being absorbed by 20 to 23 weeks. No tissue reaction to the implants was noted at any period.
In Vitro Evaluation: The drawn fibers exhibited a 43% decrease in mass after immersion in the phosphate buffer at 37° C. for 28 days.
EXAMPLE V 67/33 Poly(trans 1,4-cyclohexylenedicarbinyl-cohexamethylene Oxalate)
Distilled diethyl oxalate (40.0 g, 0.274 mol), recrystallized trans 1,4-cyclohexanedimethanol (25.9 g, 0.180 mol), 1,6-hexanediol (10.6 g, 0.0897 mol), and stannous octoate (0.33 M in toluene; 0.16 ml. 0.053 mmol) was added to a glass reactor equipped for mechanical stirring. The prepolymer was formed by heating the mixture under nitrogen at 120° C. for 9 hours, followed by 125° C. for 9 hours while collecting the distillates. The prepolymer was cooled, then reheated in vacuo (0.03 mm Hg) and maintained at 80, 120, 150, 170 and 180° C. for 1, 2, 2, 3 and 1.5 hours, respectively. The postpolymerization of the polymer melt was completed by heating at 195° C. for 6 hours while continuing to stir and remove distillates. The polymer was cooled, isolated, ground, and then dried at room temperature.
Polymer Characterization: ηinh in CHCl3 =0.49. DSC (20° C./min.): Tm =179° C.
Polymer Melt Spinning: The polymer was spun at 175° C. using an Instron Rheometer with a 30 mil die. The resulting fibers were subsequently drawn 4l× at 50° C.
Fiber Properties: Diameter=9.3 mils, straight tensile stength=2.65×104 psi, knot tensile strength=2.21×104 psi, modulus=3.7×105 psi.
In Vivo Evaluation, Tissue Reaction: Two centimeter long samples of sterilized (by γ-radiation, 2.5 Mrads) drawn fiber were implanted subcutaneously in the abdominal wall of young female Long Evans strain rats. At intervals of 3, 14, 28, 56 and 90 days, two rats were sacrificed for examination of implants. The skin containing the fibers was excised and affixed to plastic sheets for preservation in formalin. Two tissue blocks were cut transversely from each site and embedded in paraffin for histologic preparation. Eight strained samples were examined at each interval for tissue reaction to the fibers. Only mild foreign body reactions were detected.
In Vivo Evaluation, Absorption: Fiber segments sterilized by γ-radiation (2.5 Mrads) approximately 2 cm in length were inserted into the ventral abdominal subcutis of Long Evans rats (100 g, female) to determine the rate of absorption of the drawn fibers. One to two rats were sacrified after various periods after implantation. The skin containing the implant sites was removed and dried. These preparations were examined and evaluated using both dissecting and transmission microscopes. Estimates of the amount of implant remaining were based on the length of the segment or fragments remaining and the decrease in the surface area made by palpating the implant in the dried hide and comparing it with a one week old preparation. Implants were fragmented at one week; migration and clumping of fragments was noted at subsequent kill periods. Evidence of degradation was first seen 16 weeks after implantation. Palpable fragments, in diminishing amounts, were present until 30 weeks. Quantitatively, about 100, 75, 45, 40, 20, 15 and 5 or less percent of the suture remained after 14, 16, 20, 23, 26, 30 and 36 weeks.
EXAMPLE VI 50/50 Poly (trans 1,4-cyclohexyldicarbinyl-cohexamethylene Oxalate
Distilled diethyl oxalate (38.0 g, 0.260 mol), recrystallized trans 1,4-cyclohexanedimethanol (20.2 g, 0.140 mol), 1,6-hexanediol (16.5 g, 0.140 mol), and stannous octoate (0.33 M in toluene, 0.16 ml, 0.053 mmol) were added under dry and oxygen-free conditions to a mechanically stirred glass reactor. Under nitrogen at one atmosphere, the mixture was heated to and maintained at 120° C. for 20 hours, while allowing the formed ethanol to distill. The prepolymer was cooled and then reheated in vacuo (0.05 mm Hg) to and maintained at 80°, 120°, 140°, 165°, 175°, 185°, and 195° C. for 1, 1, 3, 3.5, 2, 1 and 1 hour respectively. The removal of the diols was continued by heating at 200° C. for 8 hours to complete the postpolymerization. The polymer was cooled, isolated, ground, and then dried in vacuo at room temperature.
Polymer Characterization: ηinh in CHCl3 =0.36. DSC (20° C./min.): Tm =138° C.
Polymer Melt Spinning: The polymer was spun at 136° C. using an Instron Rheometer (40 mil die) and was immediately drawn 5× at 53° C.
Fiber Properties:
X-ray Data: Major reflections correspond to 8.9 (W), 4.84 (M), 4.41 (S), and 5.40 A (W) d-spacings; 36% crystallinity.
Physical Properties: Diameter=10.6 mils, straight tensile strength=1.36×104 psi, knot tensile strength=1.13×104 psi, modulus=1.33×105 psi, elongation=27%.
In Vivo Evaluation: Sterilized (by γ-radiation) drawn fiber segments (2 centimeters in length) were implanted into the ventral abdominal subcutis for study of the rate of absorption and tissue reaction.
At one week the implants were fragmented, clumping, and migrating, with the bulk of the suture being absorbed between 6 to 11 weeks. Thereafter, fragments with scattered birefringent particles or birefringent particles in a shelllike outline were observed. The birefringent particles decreased in amount until at 36 weeks only a few widely scattered particles were noted.
Only mild foreign body reactions were observed to be elicited by the sterilized drawn fiber segments during the test intervals of 3, 14, 28, 48, 90 and 180 day post implantation.
In Vitro Evaluation: Undrawn fibers exhibited a 57 percent decrease in their initial mass after immersion in phosphate buffer at 37° C. for 28 days.
EXAMPLE VII 50/50 Poly (trans 1,4-cyclohexyldicarbinyl-cohexamethylene Oxalate)
Distilled diethyl oxalate (58.5 g, 0.400 mol), recrystallized trans 1,4-cyclohexanedimethanol (cis isomer content=0.7%; 29.7 g, 0.206 mol), 1,6-hexanediol (24.3 g, 0.206 mol), and stannous oxalate (16.5 mg, 0.080 mmols), were added under dry and oxygen-free conditions to a mechanically stirred glass reactor. The mixture was heated under nitrogen at one atmosphere to and maintained at 120° and 160° C. for 3 and 2 hours respectively while allowing the formed ethanol to distill. The prepolymer was cooled and then reheated in vacuo (0.05 mm Hg) and maintained at 170°, 190° and 205° C. for 3, 2.5 and 3 hours respectively while continuing to remove excess and formed diol to complete the postpolymerization. The polymer was cooled, isolated, ground, and then dried in vacuo at room temperature.
Polymer Characterization: ηinch in HFlP=1.07 DSC (20° C./min.) Tm =132° C.
Polymer Melt Spinning: The polymer was spun at 150° C. using an Instron Rheometer (40 mil die) and was drawn 4X at 50° C. followed by 1.5X at 72° C.
Fiber Properties:
X-ray Data: Major reflections correspond to 9.11 (MS), 4.82 (S), 4.60 (W), 4.37 (S) and 3.45 A (W) d-spacings; 46% crystallinity.
Physical Properties: Diameter=7.6. straight tensile strength=51,300 psi, knot. tensile strength=36.400 psi, elongation=31% .
EXAMPLE VIII 30/70 Poly (trans 1,4-cyclohexylenedicarbinyl-cohexamethylene Oxalate)
Distilled diethyl oxalate (36.5 g, 0.250 mol), recrystallized trans 1,4-cyclohexanedimethanol (11.5 g, 0.0797 mol), 1,6 hexanediol (22.4 g, 0.190 mol), and stannous octoate (0.33 M in toluene; 0.16 ml, 0.053 mmol) were added under dry and oxygen-free conditions to a mechanically stirred reactor. The mixture was heated to and maintained at 125, 140 and 160° C. for 2, 2 and 1 hour, respectively, under nitrogen at one atmosphere while allowing the formed ethanol to distill. The prepolymer was cooled and then reheated in vacuo (0.1 mm Hg) and maintained at 150° and 185° C. for 16 and 3 hours, respectively. The postpolymerization was completed by maintaining the polymer at 200° C. for 5.5 hours while continuing to remove the diols under vacuum. The polymer was then cooled, isolated, ground and dried in vacuo at room temperature.
Polymer Characterization: ηinh in CHCl3 =0.82. DSC (20° C./min): Tm =85° C.
Polymer Melt Spinning: The polymer was spun at 125° C. using an Instron Rheometer with a 40 mil die. The fiber was quenched in ice water, wound, dried in vacuo at room temperature, and subsequently drawn 5.6X at room temperature, followed by annealing at 55° C.
Fiber Properties: Diameter 8.3 mils, straight tensile strength 5.18×104 psi, knot tensile strength 3.51×104 psi, modulus 2.11×105 and elongation 50%.
In Vivo Evaluation: Sterilized (by γ-radiation, 2.5 Mrads), drawn fibers (9.8 mil diameter; 3.64×104 psi straight tensile strength; 2.34×104 psi knot tensile strength; 1.47×105 psi modulus; and an elongation of 45%) were implanted into the gluteal msucles of rats to determine their absorption and tissue response characteristics at 5, 21, 42 and 150 days post implantation.
At the 42 day period, there was no evidence of any morphologic changes of the implant sites indicating absorption. At the 150 day period, the fibers had a median value of 2 percent suture cross sectional area remaining (with a range of 0 to 20 percent).
Foreign body tissue responses to the samples were in the slight range at 5, 21 and 42 day periods and in the minimal range at the 150 day period.
In Vitro Evaluation: Drawn fibers possessing physical properties similar to those of fibers used in the in vivo testing exhibiting a 100% decrease in their initial mass after 141 days of immersion in phosphate buffer at 37° C.
EXAMPLE IX 5/95 Poly (trans 1,4-cyclohexylenedicarbonyl-cohexamethylene Oxalate)
Distilled diethyl oxalate (19.0 g, 0.130 mol), recrystallized trans 1,4-cyclohexanedimethanol (1.0 g, 0.0069 mol), 1,6-hexanediol (16.3 g, 0.138 mol), and stannous octoate (0.33 M in toluene; 0.08 ml, 0.026 mmol) were added under dry and oxygen-free conditions to a glass reactor equipped for magnetic stirring. The prepolymer was formed by heating the mixture at 120° C. for 3 hours under nitrogen at one atmosphere while allowing the formed ethanol to distill, followed by 160° C. for 2 hours. The prepolymer was heated and maintained at 205° C. for 8 hours in vacuo (0.05 mm Hg). The polymer was then cooled, isolated, ground, and dried at room temperature.
Polymer Characterization: ηinh in CHCl3 =0.88. DSC (20° C./min): Tm =69° C. TGA (20° C./min. under N2): Less than 0.5% weight loss at 275° C. was recorded.
Polymer Melt Spinning: The polymer was spun in an Instron Rheometer using 30 mil die at 85° C. The fibers were quenched in ice water and subsequently drawn 5X at room temperature.
Fiber Properties: Diameter=14.7 mils, straight tensile strength=1.36×104 psi, knot tensile strength=1.41×104 psi, modulus=4.8×104 psi, elongation=90%.
In Vitro Evaluation: The drawn fibers exhibited a 93 percent decrease in their initial mass after immersion in phosphate buffer at 37° C. for 42 days.
EXAMPLE X 58/42 Poly (1,4-phenylenedicarbinyl-co-hexamethylene Oxalate)
Diethyl oxalate (14.6 g, 0.100 mols), recrystallized 1,4-benzenedimethanol (6.9 g, 0.050 mols), 1,6-hexanediol (8.3 g, 0.070 mols), and Tyzor TOT: catalyst (0.4 ml of a 1% solution) were added under dry and oxygen-free conditions to a glass reactor equipped for stirring. The prepolymer was formed by heating under nitrogen at one atmosphere at 140° C. for 4 hours while allowing the formed ethanol to distill. The mixture was then heated in vacuo (0.1 mm Hg) at 165° C. for 22 hours while continuing to remove distillates. A postpolymerization was conducted at 180, 190, and 200° C. for 2, 1 and 4 hours respectively. The polymer was cooled, ground and dried.
Polymer Characterization: ηinh in HFlP=0.48. DSC (10° C./min): Tm =170° C. TGA (10° C./min in N2): Less than 1% cummulative weight loss experienced at 250° C.
Polymer Melt Spinning: The polymer was spun at 166° C. using an Instron Rheometer equipped with a 30 mil die.
In Vitro Evaluation: Immersion of a molded disc, 2.2 l cm in diameter, for 8 and 78 days in phosphate buffer at 37° C. resulted in a loss of 3 and 99 percent of the initial mass, respectively.
EXAMPLE XI 56/44 Poly (1,4-phenylenedicarbinyl-co-hexamethylene Oxalate)
Dibutyl oxalate (20.2 g, 0.100 mols), 1,4-benzenedimethanol (8.3 g, 0.060 mols), 1,6-hexanediol (5.6 g, 0.047 mols), and tetraisopropylorthotitanate catalyst (0.3 ml, of a 0.01 M solution) were added under dry and oxygen-free conditions to a glass reactor equipped for magnetic stirring. The prepolymer was formed by heating at 140, and 160° C. for 1, and 17 hours respectively under nitrogen at one atmosphere while allowing the formed butanol to distill. The pressure was reduced (0.2 mm Hg) while continuing to heat at 160° C. for an additional hour. The postpolymerization of the polymer melt was completed by heating at 180° C. and 200° C. for 2, and 3.5 hours, respectively, while continuing to remove distillates. The polymer was cooled, and isolated,
Polymer Characterization: ηinh in HFlP=0.42. DSC (10° C./min): Tm =165° C. TGA (10° C./min in N2): Less than 1% cummulative weight loss experienced at 250° C.
In Vitro Evaluation: Immersion of a molded disc, 2.2 cm in diameter, for 7 and 77 days, in phosphate buffer at 37° C. resulted in a loss of 3 and 56 percent of the initial mass, respectively.
EXAMPLE XII 50/50 Poly (1,4-phenylenedicarbinyl-co-hexamethylene Oxalate)
In a manner similar to that employed in Examples X and XI, the above identified copolymer having the following characteristics was produced:
DSC (10° C./min): Tm =175° C.
TGA (10° C./min, in N2): Less than 1% cummulative weight loss experienced at 250° C.
In Vitro Evaluation: Immersion of a molded disc, 2.2 cm in diameter, for 8 and 78 days in phosphate buffer at 37° C. resulted in a loss of 6 and 54 percent of the initial mass, respectively.
While the preceding examples have been directed to the preparation of specific copolymers of polyoxalates, these examples are for purposes of illustration only and are not limiting of the invention.
Many different embodiments of this invention will be apparent to those skilled in the art and may be made without departing from the spirit and scope thereof. It is accordingly understood that this invention is not limited to the specific embodiments thereof except as defined in the appended claims.

Claims (8)

We claim:
1. Isomorphic polyoxalate polymers consisting essentially of units of cyclic and linear oxalates and having the general formula ##STR3## wherein each R is ##STR4## and from about 5 to 95 mol percent of the R units are I; A is trans 1,4-cyclohexylene or p-phenylene, n is 1 or 2 and is the same for I and II, and x is the degree of polymerization resulting in a polymer having an inherent viscosity of at least 0.3 as determined on a 1 gm per liter solution of polymer in chloroform or hexafluoro-isopropanol at 25° C.
2. The polymer of claim 1 wherein n is 1 and A is trans 1,4-cyclohexylene.
3. The polymer of claim 1 wherein n is 2 and A is trans 1,4-cyclohexylene.
4. The polymer of claim 1 wherein from 40 to 75 mol percent of the R groups are comprised of units of formula I.
5. The polymer of claim 1 wherein n is 1 and A is p-phenylene.
6. The polymer of claim 1 wherein n is 2 and A is p-phenylene.
7. A polymer of claim 1 having an inherent viscosity of at least about 0.5.
8. A polymer of claim 1 which is fiber forming.
US05/915,500 1977-01-19 1978-06-14 Isomorphic copolyoxalates and sutures thereof Expired - Lifetime US4208511A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US05/915,500 US4208511A (en) 1977-01-19 1978-06-14 Isomorphic copolyoxalates and sutures thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US05/752,374 US4141087A (en) 1977-01-19 1977-01-19 Isomorphic copolyoxalates and sutures thereof
US05/915,500 US4208511A (en) 1977-01-19 1978-06-14 Isomorphic copolyoxalates and sutures thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US05/752,374 Continuation-In-Part US4141087A (en) 1977-01-19 1977-01-19 Isomorphic copolyoxalates and sutures thereof

Publications (1)

Publication Number Publication Date
US4208511A true US4208511A (en) 1980-06-17

Family

ID=27115578

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/915,500 Expired - Lifetime US4208511A (en) 1977-01-19 1978-06-14 Isomorphic copolyoxalates and sutures thereof

Country Status (1)

Country Link
US (1) US4208511A (en)

Cited By (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4388926A (en) * 1980-12-22 1983-06-21 Ethicon, Inc. High compliance monofilament surgical sutures comprising poly[alkylene terephthalate-co-(2-alkenyl or alkyl)succinate]
JPS6096257A (en) * 1983-09-20 1985-05-29 アライド・コ−ポレ−シヨン Artificial organ
US4603695A (en) * 1983-07-05 1986-08-05 Japan Medical Supply Co., Ltd. Use of molded polymeric material for preventing adhesion of vital tissues
US4670286A (en) * 1983-09-20 1987-06-02 Allied Corporation Method of forming prosthetic devices
US4915893A (en) * 1982-07-16 1990-04-10 Medtronic, Inc. Method of preparing polyester filament material
FR2651991A1 (en) * 1989-09-15 1991-03-22 Serres Patrick Method for forming surgical sutures/ligatures and device for carrying out this method
US5110852A (en) * 1982-07-16 1992-05-05 Rijksuniversiteit Te Groningen Filament material polylactide mixtures
WO1994020296A1 (en) * 1993-03-05 1994-09-15 Baylor University Poly (alkylene dicarboxylates) and syntheses thereof
US5426218A (en) * 1993-03-05 1995-06-20 Baylor University Bis (tetraalkylammonium) oxalate
US5561212A (en) * 1993-03-05 1996-10-01 Baylor University Poly(methylene oxalate), a new composition of matter
US20030003127A1 (en) * 2001-06-27 2003-01-02 Ethicon, Inc. Porous ceramic/porous polymer layered scaffolds for the repair and regeneration of tissue
US20030021827A1 (en) * 2001-07-16 2003-01-30 Prasanna Malaviya Hybrid biologic/synthetic porous extracellular matrix scaffolds
US20030033022A1 (en) * 2001-07-16 2003-02-13 Plouhar Pamela Lynn Cartilage repair and regeneration device and method
US20030036797A1 (en) * 2001-07-16 2003-02-20 Prasanna Malaviya Meniscus regeneration device and method
US20030044444A1 (en) * 2001-07-16 2003-03-06 Prasanna Malaviya Porous extracellular matrix scaffold and method
US20030049299A1 (en) * 2001-07-16 2003-03-13 Prasanna Malaviya Porous delivery scaffold and method
US6575986B2 (en) 2001-02-26 2003-06-10 Ethicon, Inc. Scaffold fixation device for use in articular cartilage repair
US6626950B2 (en) 2001-06-28 2003-09-30 Ethicon, Inc. Composite scaffold with post anchor for the repair and regeneration of tissue
EP1410811A1 (en) 2002-10-18 2004-04-21 Ethicon, Inc. Biocompatible scaffolds with tissue fragments
EP1410810A1 (en) 2002-10-18 2004-04-21 Ethicon, Inc. Biocompatible scaffold for ligament or tendon repair
US20040086517A1 (en) * 2001-05-11 2004-05-06 Tenhuisen Kevor S. Method of modulating the immune system in an animal to an antigen
US6743232B2 (en) 2001-02-26 2004-06-01 David W. Overaker Tissue scaffold anchor for cartilage repair
US20040204677A1 (en) * 2001-09-28 2004-10-14 Ethicon, Inc. Methods and devices for treating diseased blood vessels
US20040243180A1 (en) * 2001-09-28 2004-12-02 Donnelly Lisa M. Absorbable bone anchor
EP1491148A1 (en) 2003-06-27 2004-12-29 DePuy Mitek, Inc. Bioabsorbable suture anchor system for use in small joints
EP1493404A1 (en) 2003-06-30 2005-01-05 DePuy Mitek, Inc. Scaffold for connective tissue repair
US20050027307A1 (en) * 2001-07-16 2005-02-03 Schwartz Herbert Eugene Unitary surgical device and method
US20050038520A1 (en) * 2003-08-11 2005-02-17 Francois Binette Method and apparatus for resurfacing an articular surface
US20050054595A1 (en) * 2003-09-08 2005-03-10 Francois Binette Chondrocyte therapeutic delivery system
US20050129729A1 (en) * 2003-09-25 2005-06-16 Schreiner George F. Stents and intra-luminal prostheses containing map kinase inhibitors
US20050149030A1 (en) * 2003-12-19 2005-07-07 Depuy Spine, Inc. Facet joint fixation system
US20050232967A1 (en) 2004-04-20 2005-10-20 Kladakis Stephanie M Nonwoven tissue scaffold
US20050249771A1 (en) * 2004-05-04 2005-11-10 Prasanna Malaviya Hybrid biologic-synthetic bioabsorbable scaffolds
US20060100679A1 (en) * 2004-08-27 2006-05-11 Dimauro Thomas Light-based implants for treating Alzheimer's disease
EP1676535A1 (en) 2004-12-29 2006-07-05 DePuy Mitek, Inc. Surgical abrasive cutting system
US20060276895A1 (en) * 2005-05-27 2006-12-07 Richard Pellegrino Intervertebral ligament having a helical bone fastener
US20060287676A1 (en) * 2005-06-15 2006-12-21 Rita Prajapati Method of intra-operative coating therapeutic agents onto sutures, composite sutures and methods of use
US20060287675A1 (en) * 2005-06-15 2006-12-21 Prajapati Rita T Method of intra-operative coating therapeutic agents onto sutures composite sutures and methods of use
US20060286289A1 (en) * 2005-06-15 2006-12-21 Rita Prajapati Method of intraoperative coating therapeutic agents onto sutures
US20070031470A1 (en) * 2004-04-20 2007-02-08 Depuy Mitek, Inc. Nonwoven tissue scaffold
US20070098645A1 (en) * 2005-10-31 2007-05-03 Agbodoe Victor B Intranasal delivery of compounds that reduce intrancranial pressure
US20070112360A1 (en) * 2005-11-15 2007-05-17 Patrick De Deyne Bioprosthetic device
US20070239235A1 (en) * 2005-03-14 2007-10-11 Dimauro Thomas M Red Light Implant For Treating Parkinson's Disease
US20070297987A1 (en) * 2006-06-26 2007-12-27 Shawn Stad Anti-Adhesion Sheet
US20080014152A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Intranasal delivery of clenbuterol across the cribriform plate and into the brain
US20080071385A1 (en) * 2003-11-26 2008-03-20 Depuy Mitek, Inc. Conformable tissue repair implant capable of injection delivery
US20080081323A1 (en) * 2006-09-29 2008-04-03 Daniel Keeley Regenerative Medicine Devices and Melt-Blown Methods of Manufacture
US7354627B2 (en) 2004-12-22 2008-04-08 Depuy Products, Inc. Method for organizing the assembly of collagen fibers and compositions formed therefrom
US20080119851A1 (en) * 2006-11-20 2008-05-22 Depuy Spine, Inc. Anterior spinal vessel protector
US20080131477A1 (en) * 2001-04-11 2008-06-05 Chin-Feng Yi Device and method for tissue engineering
US20080268016A1 (en) * 2007-04-24 2008-10-30 Fang Carrie H Engineered Renal Tissue
EP1987850A1 (en) 2000-12-21 2008-11-05 Ethicon, Incorporated Reinforced tissue implants and methods of manufacture and use
US20080299173A1 (en) * 2007-06-01 2008-12-04 Johnson & Johnson Regenerative Therapeutics, Llc Chondrocyte container and method of use
EP2033648A2 (en) 2001-04-26 2009-03-11 pSivida Inc Sustained release drug delivery system containing codrugs
US20090088809A1 (en) * 2007-09-28 2009-04-02 Michael Alan Fisher Anti-Microbial Implant
US20090106360A1 (en) * 2007-06-08 2009-04-23 Jin Peng Content delivery method and system, network device, and mobile data service platform
US20090130163A1 (en) * 2005-02-18 2009-05-21 Abraxis Bio Scoence, Inc. Drugs With Improved Hydrophobicity For Incorporation in Medical Devices
US20090162386A1 (en) * 2003-09-08 2009-06-25 Depuy Mitek, Inc. Chondrocyte therapeutic delivery system
WO2009100908A1 (en) * 2008-02-13 2009-08-20 Jotun A/S Antifouling composition
US7595062B2 (en) 2005-07-28 2009-09-29 Depuy Products, Inc. Joint resurfacing orthopaedic implant and associated method
US20090299034A1 (en) * 2007-08-01 2009-12-03 Mabel Alamino Cejas Collagen-related peptides
US20090325963A1 (en) * 2008-06-27 2009-12-31 Sean Lilienfeld Iontophoretic Delivery of Curcumin and Curcumin Analogs for the Treatment of Alzheimer's Disease
US20100021527A1 (en) * 2008-07-25 2010-01-28 Chunlin Yang Collagen-related peptides and uses thereof and hemostatic foam substrates
US20100087527A1 (en) * 2007-04-17 2010-04-08 Codman & Shurtleff, Inc. Curcumin Derivatives
WO2010042049A1 (en) 2008-10-10 2010-04-15 Milux Holding S.A. Composition, method and device for stabilizing implanted hydraulic devices
US7723515B1 (en) 2009-01-26 2010-05-25 Codman & Shurtleff, Inc. Methylene blue—curcumin analog for the treatment of alzheimer's disease
US7745670B2 (en) 2008-06-27 2010-06-29 Codman & Shurtleff, Inc. Curcumin-Resveratrol hybrid molecule
US20100198316A1 (en) * 2009-02-04 2010-08-05 Richard Toselli Intracranial Red Light Treatment Device For Chronic Pain
US7819918B2 (en) 2001-07-16 2010-10-26 Depuy Products, Inc. Implantable tissue repair device
US20100286585A1 (en) * 2009-01-26 2010-11-11 Codman & Shurtleff, Inc. Shunt Delivery of Curcumin
US20100292512A1 (en) * 2008-02-12 2010-11-18 Dimauro Thomas M Methylated Curcumin-Resveratrol Hybrid Molecules for Treating Cancer
US7871440B2 (en) 2006-12-11 2011-01-18 Depuy Products, Inc. Unitary surgical device and method
US20110022130A1 (en) * 2005-06-16 2011-01-27 Dimauro Thomas M Intranasal Red Light Probe For Treating Alzheimer's Disease
US7901461B2 (en) 2003-12-05 2011-03-08 Ethicon, Inc. Viable tissue repair implants and methods of use
US20110066244A1 (en) * 2009-09-11 2011-03-17 William Frasier Minimally Invasive Intervertebral Staple Distraction Devices
US20110066192A1 (en) * 2009-09-15 2011-03-17 William Frasier Expandable Ring Intervertebral Fusion Device
EP2325193A2 (en) 2001-11-02 2011-05-25 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of RNA interference
WO2011061295A1 (en) 2009-11-19 2011-05-26 Blue Medical Devices Bv Narrow profile composition-releasing expandable medical balloon catheter
US8016867B2 (en) 1999-07-23 2011-09-13 Depuy Mitek, Inc. Graft fixation device and method
US8076294B2 (en) 2007-08-01 2011-12-13 Advanced Technologies And Regenerative Medicine, Llc. Collagen-related peptides and uses thereof
EP2422712A2 (en) 2010-08-30 2012-02-29 DePuy Mitek, Inc. Knotless suture anchor
EP2422714A2 (en) 2010-08-30 2012-02-29 DePuy Mitek, Inc. Anchor driver with suture clutch
EP2422713A2 (en) 2010-08-30 2012-02-29 DePuy Mitek, Inc. Knotless suture anchor and driver
EP2422711A2 (en) 2010-08-30 2012-02-29 DePuy Mitek, Inc. Knotless suture anchor
EP2422715A2 (en) 2010-08-30 2012-02-29 DePuy Mitek, Inc. Suture anchor and threader
WO2012088496A2 (en) 2010-12-23 2012-06-28 Depuy Mitek, Inc. Adjustable anchor systems and methods
US8337537B2 (en) 2001-07-16 2012-12-25 Depuy Products, Inc. Device from naturally occurring biologically derived materials
EP2574284A1 (en) 2011-09-30 2013-04-03 DePuy Mitek, Inc. Knotless suture anchor
EP2574283A1 (en) 2011-09-28 2013-04-03 DePuy Mitek, Inc. Knotless suture anchor
US8449561B2 (en) 1999-07-23 2013-05-28 Depuy Mitek, Llc Graft fixation device combination
US8691259B2 (en) 2000-12-21 2014-04-08 Depuy Mitek, Llc Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration
US8790370B2 (en) 2012-03-30 2014-07-29 Depuy Mitek, Llc Surgical filament assemblies
US8814905B2 (en) 2010-11-23 2014-08-26 Depuy Mitek, Llc Surgical filament snare assemblies
US8821545B2 (en) 2010-11-23 2014-09-02 Depuy Mitek, Llc Surgical filament snare assemblies
US8821543B2 (en) 2010-12-23 2014-09-02 Depuy Mitek, Llc Adjustable anchor systems and methods
US8845733B2 (en) 2010-06-24 2014-09-30 DePuy Synthes Products, LLC Lateral spondylolisthesis reduction cage
US8895045B2 (en) 2003-03-07 2014-11-25 Depuy Mitek, Llc Method of preparation of bioabsorbable porous reinforced tissue implants and implants thereof
US8894684B2 (en) 2012-05-07 2014-11-25 Medos International Sàrl Systems, devices, and methods for securing tissue using a suture having one or more protrusions
US9060763B2 (en) 2012-05-07 2015-06-23 Medos International Sàrl Systems, devices, and methods for securing tissue
US9060764B2 (en) 2012-05-07 2015-06-23 Medos International Sàrl Systems, devices, and methods for securing tissue
EP2898856A2 (en) 2013-07-18 2015-07-29 Medos International Sarl Devices for positioning and securing ligament grafts
US9192373B2 (en) 2012-12-27 2015-11-24 Medos International Sàrl Surgical constructs and methods for securing tissue
US9226764B2 (en) 2012-03-06 2016-01-05 DePuy Synthes Products, Inc. Conformable soft tissue removal instruments
US9248216B2 (en) 2002-12-03 2016-02-02 Boston Scientific Scimed, Inc. Medical devices for delivery of therapeutic agents
US9248028B2 (en) 2011-09-16 2016-02-02 DePuy Synthes Products, Inc. Removable, bone-securing cover plate for intervertebral fusion cage
US9320914B2 (en) 2008-03-03 2016-04-26 DePuy Synthes Products, Inc. Endoscopic delivery of red/NIR light to the subventricular zone
US9345567B2 (en) 2012-05-07 2016-05-24 Medos International Sàrl Systems, devices, and methods for securing tissue using snare assemblies and soft anchors
US9352071B2 (en) 2013-03-14 2016-05-31 Ethicon, Inc. Method of forming an implantable device
EP3087955A1 (en) 2009-07-10 2016-11-02 Kirk Promotion LTD. Hip joint device
US9526620B2 (en) 2009-03-30 2016-12-27 DePuy Synthes Products, Inc. Zero profile spinal fusion cage
US9662225B2 (en) 2012-03-06 2017-05-30 DePuy Synthes Products, Inc. Nubbed plate
US9687354B2 (en) 2008-03-26 2017-06-27 DePuy Synthes Products, Inc. Posterior intervertebral disc inserter and expansion techniques
US9737293B2 (en) 2013-03-15 2017-08-22 Medos International Sàrl Surgical constructs with collapsing suture loop and methods for securing tissue
US9763655B2 (en) 2012-09-20 2017-09-19 Medos International Sarl Systems, devices, and methods for securing tissue using hard anchors
US9931224B2 (en) 2009-11-05 2018-04-03 DePuy Synthes Products, Inc. Self-pivoting spinal implant and associated instrumentation
US10022245B2 (en) 2012-12-17 2018-07-17 DePuy Synthes Products, Inc. Polyaxial articulating instrument
US10123862B2 (en) 2013-03-14 2018-11-13 Ethicon, Inc. Randomly uniform three dimensional tissue scaffold of absorbable and non-absorbable materials
US10182921B2 (en) 2012-11-09 2019-01-22 DePuy Synthes Products, Inc. Interbody device with opening to allow packing graft and other biologics
US10206787B2 (en) 2006-12-22 2019-02-19 Medos International Sarl Composite vertebral spacers and instrument
USRE47266E1 (en) 2005-03-14 2019-03-05 DePuy Synthes Products, Inc. Light-based implants for treating Alzheimer's disease
US10335289B2 (en) 2010-09-23 2019-07-02 DePuy Synthes Products, Inc. Stand alone intervertebral fusion device
US10369015B2 (en) 2010-09-23 2019-08-06 DePuy Synthes Products, Inc. Implant inserter having a laterally-extending dovetail engagement feature
US10500062B2 (en) 2009-12-10 2019-12-10 DePuy Synthes Products, Inc. Bellows-like expandable interbody fusion cage
CN110914335A (en) * 2017-05-18 2020-03-24 阿凡田知识中心有限公司 Polyester copolymer
WO2020106144A1 (en) * 2018-11-22 2020-05-28 Avantium Knowledge Centre B.V. Process for the production of one or more polyester copolymers, method for the preparation of one or more oligomers, oligomer composition and polyester copolymer
US10940016B2 (en) 2017-07-05 2021-03-09 Medos International Sarl Expandable intervertebral fusion cage
US10966843B2 (en) 2017-07-18 2021-04-06 DePuy Synthes Products, Inc. Implant inserters and related methods
US11045331B2 (en) 2017-08-14 2021-06-29 DePuy Synthes Products, Inc. Intervertebral implant inserters and related methods
US11369490B2 (en) 2011-03-22 2022-06-28 DePuy Synthes Products, Inc. Universal trial for lateral cages
US11395865B2 (en) 2004-02-09 2022-07-26 DePuy Synthes Products, Inc. Scaffolds with viable tissue
US11432942B2 (en) 2006-12-07 2022-09-06 DePuy Synthes Products, Inc. Intervertebral implant
US11452607B2 (en) 2010-10-11 2022-09-27 DePuy Synthes Products, Inc. Expandable interspinous process spacer implant
US11529241B2 (en) 2010-09-23 2022-12-20 DePuy Synthes Products, Inc. Fusion cage with in-line single piece fixation
US11622868B2 (en) 2007-06-26 2023-04-11 DePuy Synthes Products, Inc. Highly lordosed fusion cage
US11806245B2 (en) 2020-03-06 2023-11-07 Eit Emerging Implant Technologies Gmbh Expandable intervertebral implant
US11850160B2 (en) 2021-03-26 2023-12-26 Medos International Sarl Expandable lordotic intervertebral fusion cage
US11850164B2 (en) 2013-03-07 2023-12-26 DePuy Synthes Products, Inc. Intervertebral implant
US11872139B2 (en) 2010-06-24 2024-01-16 DePuy Synthes Products, Inc. Enhanced cage insertion assembly

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032993A (en) * 1974-06-28 1977-07-05 Rhone-Poulenc Industries Bioresorbable surgical articles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032993A (en) * 1974-06-28 1977-07-05 Rhone-Poulenc Industries Bioresorbable surgical articles

Cited By (304)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4388926A (en) * 1980-12-22 1983-06-21 Ethicon, Inc. High compliance monofilament surgical sutures comprising poly[alkylene terephthalate-co-(2-alkenyl or alkyl)succinate]
US4915893A (en) * 1982-07-16 1990-04-10 Medtronic, Inc. Method of preparing polyester filament material
US5110852A (en) * 1982-07-16 1992-05-05 Rijksuniversiteit Te Groningen Filament material polylactide mixtures
US4603695A (en) * 1983-07-05 1986-08-05 Japan Medical Supply Co., Ltd. Use of molded polymeric material for preventing adhesion of vital tissues
JPS6096257A (en) * 1983-09-20 1985-05-29 アライド・コ−ポレ−シヨン Artificial organ
US4594407A (en) * 1983-09-20 1986-06-10 Allied Corporation Prosthetic devices derived from krebs-cycle dicarboxylic acids and diols
US4670286A (en) * 1983-09-20 1987-06-02 Allied Corporation Method of forming prosthetic devices
FR2651991A1 (en) * 1989-09-15 1991-03-22 Serres Patrick Method for forming surgical sutures/ligatures and device for carrying out this method
US5561212A (en) * 1993-03-05 1996-10-01 Baylor University Poly(methylene oxalate), a new composition of matter
US5426218A (en) * 1993-03-05 1995-06-20 Baylor University Bis (tetraalkylammonium) oxalate
US5668224A (en) * 1993-03-05 1997-09-16 Baylor University Poly(alkylene dicarboxylates) and syntheses thereof
US5837381A (en) * 1993-03-05 1998-11-17 Univ Baylor Laminates of glass or metal and poly(alkylene dicarboxylates)
US6011133A (en) * 1993-03-05 2000-01-04 Baylor University Laminates of glass or metal and poly(alkylene dicarboxylates) and syntheses thereof
WO1994020296A1 (en) * 1993-03-05 1994-09-15 Baylor University Poly (alkylene dicarboxylates) and syntheses thereof
US8016867B2 (en) 1999-07-23 2011-09-13 Depuy Mitek, Inc. Graft fixation device and method
US8449561B2 (en) 1999-07-23 2013-05-28 Depuy Mitek, Llc Graft fixation device combination
US8691259B2 (en) 2000-12-21 2014-04-08 Depuy Mitek, Llc Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration
EP1987850A1 (en) 2000-12-21 2008-11-05 Ethicon, Incorporated Reinforced tissue implants and methods of manufacture and use
US6575986B2 (en) 2001-02-26 2003-06-10 Ethicon, Inc. Scaffold fixation device for use in articular cartilage repair
US6743232B2 (en) 2001-02-26 2004-06-01 David W. Overaker Tissue scaffold anchor for cartilage repair
US20080131477A1 (en) * 2001-04-11 2008-06-05 Chin-Feng Yi Device and method for tissue engineering
US7604817B2 (en) 2001-04-11 2009-10-20 Ethicon Endo-Surgery, Inc. Method for promoting growth of tissue
EP2033648A2 (en) 2001-04-26 2009-03-11 pSivida Inc Sustained release drug delivery system containing codrugs
EP2283845A1 (en) 2001-04-26 2011-02-16 pSivida Inc. Sustained release drug delivery system containing codrugs
US20050106129A1 (en) * 2001-05-11 2005-05-19 Tenhuisen Kevor S. Method of obtaining immune cells from an animal
US20040086517A1 (en) * 2001-05-11 2004-05-06 Tenhuisen Kevor S. Method of modulating the immune system in an animal to an antigen
US7094419B2 (en) 2001-05-11 2006-08-22 Tenhuisen Kevor S Method of obtaining immune cells from an animal
US6958158B2 (en) 2001-05-11 2005-10-25 Ortho-Mcneil Pharmaceutical, Inc. Immune modulation device for use in animals
US20030003127A1 (en) * 2001-06-27 2003-01-02 Ethicon, Inc. Porous ceramic/porous polymer layered scaffolds for the repair and regeneration of tissue
EP1604696A1 (en) 2001-06-27 2005-12-14 Ethicon, Inc. Porous ceramic/porous polymer layered scaffolds for the repair and regeneration of tissue
US6626950B2 (en) 2001-06-28 2003-09-30 Ethicon, Inc. Composite scaffold with post anchor for the repair and regeneration of tissue
US8012205B2 (en) * 2001-07-16 2011-09-06 Depuy Products, Inc. Cartilage repair and regeneration device
US8092529B2 (en) 2001-07-16 2012-01-10 Depuy Products, Inc. Meniscus regeneration device
US7163563B2 (en) 2001-07-16 2007-01-16 Depuy Products, Inc. Unitary surgical device and method
US20050027307A1 (en) * 2001-07-16 2005-02-03 Schwartz Herbert Eugene Unitary surgical device and method
US20030021827A1 (en) * 2001-07-16 2003-01-30 Prasanna Malaviya Hybrid biologic/synthetic porous extracellular matrix scaffolds
US7819918B2 (en) 2001-07-16 2010-10-26 Depuy Products, Inc. Implantable tissue repair device
US8337537B2 (en) 2001-07-16 2012-12-25 Depuy Products, Inc. Device from naturally occurring biologically derived materials
US20030033022A1 (en) * 2001-07-16 2003-02-13 Plouhar Pamela Lynn Cartilage repair and regeneration device and method
US20030049299A1 (en) * 2001-07-16 2003-03-13 Prasanna Malaviya Porous delivery scaffold and method
US8025896B2 (en) 2001-07-16 2011-09-27 Depuy Products, Inc. Porous extracellular matrix scaffold and method
US20030036797A1 (en) * 2001-07-16 2003-02-20 Prasanna Malaviya Meniscus regeneration device and method
US20030044444A1 (en) * 2001-07-16 2003-03-06 Prasanna Malaviya Porous extracellular matrix scaffold and method
US7914808B2 (en) 2001-07-16 2011-03-29 Depuy Products, Inc. Hybrid biologic/synthetic porous extracellular matrix scaffolds
US7611484B2 (en) 2001-09-28 2009-11-03 Ethicon, Inc. Methods and devices for treating diseased blood vessels
US20040204677A1 (en) * 2001-09-28 2004-10-14 Ethicon, Inc. Methods and devices for treating diseased blood vessels
US8449584B2 (en) 2001-09-28 2013-05-28 Depuy Mitek, Llc Absorbable bone anchor
US20040243180A1 (en) * 2001-09-28 2004-12-02 Donnelly Lisa M. Absorbable bone anchor
US7875064B2 (en) 2001-09-28 2011-01-25 Ethicon, Inc. Absorbable bone anchor
US20110087283A1 (en) * 2001-09-28 2011-04-14 Depuy Mitek, Inc. Absorbable bone anchor
EP2325193A2 (en) 2001-11-02 2011-05-25 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of RNA interference
EP1410811A1 (en) 2002-10-18 2004-04-21 Ethicon, Inc. Biocompatible scaffolds with tissue fragments
US8637066B2 (en) 2002-10-18 2014-01-28 Depuy Mitek, Llc Biocompatible scaffold for ligament or tendon repair
EP1410810A1 (en) 2002-10-18 2004-04-21 Ethicon, Inc. Biocompatible scaffold for ligament or tendon repair
US20040078077A1 (en) * 2002-10-18 2004-04-22 Francois Binette Biocompatible scaffold for ligament or tendon repair
US7824701B2 (en) 2002-10-18 2010-11-02 Ethicon, Inc. Biocompatible scaffold for ligament or tendon repair
US9511171B2 (en) 2002-10-18 2016-12-06 Depuy Mitek, Llc Biocompatible scaffolds with tissue fragments
US10603408B2 (en) 2002-10-18 2020-03-31 DePuy Synthes Products, Inc. Biocompatible scaffolds with tissue fragments
US9248216B2 (en) 2002-12-03 2016-02-02 Boston Scientific Scimed, Inc. Medical devices for delivery of therapeutic agents
US8895045B2 (en) 2003-03-07 2014-11-25 Depuy Mitek, Llc Method of preparation of bioabsorbable porous reinforced tissue implants and implants thereof
EP1491148A1 (en) 2003-06-27 2004-12-29 DePuy Mitek, Inc. Bioabsorbable suture anchor system for use in small joints
US9211362B2 (en) 2003-06-30 2015-12-15 Depuy Mitek, Llc Scaffold for connective tissue repair
JP2005021685A (en) * 2003-06-30 2005-01-27 Depuy Mitek Inc Scaffold for connective tissue repair
EP1493404A1 (en) 2003-06-30 2005-01-05 DePuy Mitek, Inc. Scaffold for connective tissue repair
US8226715B2 (en) 2003-06-30 2012-07-24 Depuy Mitek, Inc. Scaffold for connective tissue repair
US20050038520A1 (en) * 2003-08-11 2005-02-17 Francois Binette Method and apparatus for resurfacing an articular surface
US10583220B2 (en) 2003-08-11 2020-03-10 DePuy Synthes Products, Inc. Method and apparatus for resurfacing an articular surface
US20090162386A1 (en) * 2003-09-08 2009-06-25 Depuy Mitek, Inc. Chondrocyte therapeutic delivery system
US9125888B2 (en) 2003-09-08 2015-09-08 Depuy Mitek, Llc Chondrocyte therapeutic delivery system
US20080181954A1 (en) * 2003-09-08 2008-07-31 Depuy Mitek, Inc. Chondrocyte Therapeutic Delivery Stystem
US20050054595A1 (en) * 2003-09-08 2005-03-10 Francois Binette Chondrocyte therapeutic delivery system
US20060292131A1 (en) * 2003-09-08 2006-12-28 Depuy Mitek, Inc. Chondrocyte Therapeutic Delivery System
US8153117B2 (en) 2003-09-08 2012-04-10 Depuy Mitek, Inc. Chondrocyte therapeutic delivery system
US7927599B2 (en) 2003-09-08 2011-04-19 Ethicon, Inc. Chondrocyte therapeutic delivery system
US8394369B2 (en) 2003-09-08 2013-03-12 Depuy Mitek, Inc. Chondrocyte therapeutic delivery system
US8354100B2 (en) 2003-09-08 2013-01-15 Depuy Mitek, Inc. Chondrocyte therapeutic delivery system
US7897384B2 (en) 2003-09-08 2011-03-01 Ethicon, Inc. Chondrocyte therapeutic delivery system
US20050129729A1 (en) * 2003-09-25 2005-06-16 Schreiner George F. Stents and intra-luminal prostheses containing map kinase inhibitors
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
US20080071385A1 (en) * 2003-11-26 2008-03-20 Depuy Mitek, Inc. Conformable tissue repair implant capable of injection delivery
US8137702B2 (en) 2003-11-26 2012-03-20 Depuy Mitek, Inc. Conformable tissue repair implant capable of injection delivery
US8496970B2 (en) 2003-11-26 2013-07-30 Depuy Mitek, Llc Conformable tissue repair implant capable of injection delivery
US7875296B2 (en) 2003-11-26 2011-01-25 Depuy Mitek, Inc. Conformable tissue repair implant capable of injection delivery
US8641775B2 (en) 2003-12-05 2014-02-04 Depuy Mitek, Llc Viable tissue repair implants and methods of use
US7901461B2 (en) 2003-12-05 2011-03-08 Ethicon, Inc. Viable tissue repair implants and methods of use
US20050149030A1 (en) * 2003-12-19 2005-07-07 Depuy Spine, Inc. Facet joint fixation system
US11395865B2 (en) 2004-02-09 2022-07-26 DePuy Synthes Products, Inc. Scaffolds with viable tissue
US8221780B2 (en) 2004-04-20 2012-07-17 Depuy Mitek, Inc. Nonwoven tissue scaffold
US20050232967A1 (en) 2004-04-20 2005-10-20 Kladakis Stephanie M Nonwoven tissue scaffold
US8137686B2 (en) 2004-04-20 2012-03-20 Depuy Mitek, Inc. Nonwoven tissue scaffold
US20070031470A1 (en) * 2004-04-20 2007-02-08 Depuy Mitek, Inc. Nonwoven tissue scaffold
US7569233B2 (en) 2004-05-04 2009-08-04 Depuy Products, Inc. Hybrid biologic-synthetic bioabsorbable scaffolds
US20050249771A1 (en) * 2004-05-04 2005-11-10 Prasanna Malaviya Hybrid biologic-synthetic bioabsorbable scaffolds
US8821559B2 (en) 2004-08-27 2014-09-02 Codman & Shurtleff, Inc. Light-based implants for treating Alzheimer's disease
US20060100679A1 (en) * 2004-08-27 2006-05-11 Dimauro Thomas Light-based implants for treating Alzheimer's disease
US7354627B2 (en) 2004-12-22 2008-04-08 Depuy Products, Inc. Method for organizing the assembly of collagen fibers and compositions formed therefrom
US8425517B2 (en) 2004-12-29 2013-04-23 Depuy Mitek, Inc. Abrasive cutting system and method
EP1676535A1 (en) 2004-12-29 2006-07-05 DePuy Mitek, Inc. Surgical abrasive cutting system
EP2896412A1 (en) 2005-02-18 2015-07-22 Abraxis BioScience, LLC Drugs with improved hydrophobicity for incorporation in medical devices
EP3345631A1 (en) 2005-02-18 2018-07-11 Abraxis BioScience, LLC Drugs with improved hydrophobicity for incorporation in medical devices
US20090130163A1 (en) * 2005-02-18 2009-05-21 Abraxis Bio Scoence, Inc. Drugs With Improved Hydrophobicity For Incorporation in Medical Devices
EP3345632A1 (en) 2005-02-18 2018-07-11 Abraxis BioScience, LLC Drugs with improved hydrophobicity for incorporation in medical devices
US8900284B2 (en) 2005-03-14 2014-12-02 DePuy Synthes Products, LLC Red light implant for treating Parkinson's disease
USRE47266E1 (en) 2005-03-14 2019-03-05 DePuy Synthes Products, Inc. Light-based implants for treating Alzheimer's disease
US20070239235A1 (en) * 2005-03-14 2007-10-11 Dimauro Thomas M Red Light Implant For Treating Parkinson's Disease
US8591579B2 (en) 2005-05-27 2013-11-26 DePuy Synthes Products, LLC Intervertebral ligament having a helical bone fastener
US9498263B2 (en) 2005-05-27 2016-11-22 DePuy Synthes Products, Inc. Prosthetic ligament having a helical bone fastener
US20060276895A1 (en) * 2005-05-27 2006-12-07 Richard Pellegrino Intervertebral ligament having a helical bone fastener
US10064663B2 (en) 2005-05-27 2018-09-04 DePuy Synthes Products, Inc. Intervertebral ligament having a helical bone fastener
US8092528B2 (en) 2005-05-27 2012-01-10 Depuy Spine, Inc. Intervertebral ligament having a helical bone fastener
US20060286289A1 (en) * 2005-06-15 2006-12-21 Rita Prajapati Method of intraoperative coating therapeutic agents onto sutures
US20060287676A1 (en) * 2005-06-15 2006-12-21 Rita Prajapati Method of intra-operative coating therapeutic agents onto sutures, composite sutures and methods of use
US20060287675A1 (en) * 2005-06-15 2006-12-21 Prajapati Rita T Method of intra-operative coating therapeutic agents onto sutures composite sutures and methods of use
US20110022130A1 (en) * 2005-06-16 2011-01-27 Dimauro Thomas M Intranasal Red Light Probe For Treating Alzheimer's Disease
US8734498B2 (en) 2005-06-16 2014-05-27 DePuy Synthes Products, LLC Intranasal red light probe for treating alzheimer's disease
US7595062B2 (en) 2005-07-28 2009-09-29 Depuy Products, Inc. Joint resurfacing orthopaedic implant and associated method
US8167920B2 (en) 2005-10-31 2012-05-01 Codman & Shurtleff, Inc. Intranasal delivery of compounds that reduce intrancranial pressure
US20070098645A1 (en) * 2005-10-31 2007-05-03 Agbodoe Victor B Intranasal delivery of compounds that reduce intrancranial pressure
US20070112360A1 (en) * 2005-11-15 2007-05-17 Patrick De Deyne Bioprosthetic device
US20070297987A1 (en) * 2006-06-26 2007-12-27 Shawn Stad Anti-Adhesion Sheet
US8709094B2 (en) 2006-06-26 2014-04-29 DePuy Synthes Products, LLC Anti-adhesion sheet
US20080014152A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Intranasal delivery of clenbuterol across the cribriform plate and into the brain
US20080081323A1 (en) * 2006-09-29 2008-04-03 Daniel Keeley Regenerative Medicine Devices and Melt-Blown Methods of Manufacture
EP1967219A2 (en) 2006-09-29 2008-09-10 Johnson & Johnson Regenerative Therapeutics, LLC Tissue growth devices
US8734517B2 (en) 2006-11-20 2014-05-27 DePuy Synthes Products, LLP Medical procedure involving protective pad
US20080119851A1 (en) * 2006-11-20 2008-05-22 Depuy Spine, Inc. Anterior spinal vessel protector
US8114159B2 (en) 2006-11-20 2012-02-14 Depuy Spine, Inc. Anterior spinal vessel protector
US11432942B2 (en) 2006-12-07 2022-09-06 DePuy Synthes Products, Inc. Intervertebral implant
US7871440B2 (en) 2006-12-11 2011-01-18 Depuy Products, Inc. Unitary surgical device and method
US11020237B2 (en) 2006-12-22 2021-06-01 Medos International Sarl Composite vertebral spacers and instrument
US10206787B2 (en) 2006-12-22 2019-02-19 Medos International Sarl Composite vertebral spacers and instrument
EP2749552A1 (en) 2007-04-17 2014-07-02 Codman & Shurtleff, Inc. Curcumin-resveratrol hybrids
US20100087527A1 (en) * 2007-04-17 2010-04-08 Codman & Shurtleff, Inc. Curcumin Derivatives
US8383865B2 (en) 2007-04-17 2013-02-26 Codman & Shurtleff, Inc. Curcumin derivatives
US20080268016A1 (en) * 2007-04-24 2008-10-30 Fang Carrie H Engineered Renal Tissue
US8592201B2 (en) 2007-06-01 2013-11-26 Depuy Mitek, Llc Chondrocyte container and method of use
US8257963B2 (en) 2007-06-01 2012-09-04 Depuy Mitek, Inc. Chondrocyte container and method of use
US20080299173A1 (en) * 2007-06-01 2008-12-04 Johnson & Johnson Regenerative Therapeutics, Llc Chondrocyte container and method of use
US20090106360A1 (en) * 2007-06-08 2009-04-23 Jin Peng Content delivery method and system, network device, and mobile data service platform
US11622868B2 (en) 2007-06-26 2023-04-11 DePuy Synthes Products, Inc. Highly lordosed fusion cage
US20090299034A1 (en) * 2007-08-01 2009-12-03 Mabel Alamino Cejas Collagen-related peptides
US8076294B2 (en) 2007-08-01 2011-12-13 Advanced Technologies And Regenerative Medicine, Llc. Collagen-related peptides and uses thereof
US11389202B2 (en) 2007-09-28 2022-07-19 De Puy Synthes Products. Inc. Anti-microbial implant
US9247973B2 (en) 2007-09-28 2016-02-02 DePuy Synthes Products, Inc. Anti-microbial implant
US20090088809A1 (en) * 2007-09-28 2009-04-02 Michael Alan Fisher Anti-Microbial Implant
US10786282B2 (en) 2007-09-28 2020-09-29 DePuy Synthes Products, Inc. Anti-microbial implant
US10064655B2 (en) 2007-09-28 2018-09-04 DePuy Synthes Products, Inc. Anti-microbial implant
US8350093B2 (en) 2008-02-12 2013-01-08 Codman & Shurtleff, Inc. Methylated curcumin-resveratrol hybrid molecules for treating cancer
US20100292512A1 (en) * 2008-02-12 2010-11-18 Dimauro Thomas M Methylated Curcumin-Resveratrol Hybrid Molecules for Treating Cancer
WO2009100908A1 (en) * 2008-02-13 2009-08-20 Jotun A/S Antifouling composition
US8575231B2 (en) 2008-02-13 2013-11-05 Jotun A/S Antifouling composition
US9546283B2 (en) 2008-02-13 2017-01-17 Jotun A/S Antifouling composition
US9320914B2 (en) 2008-03-03 2016-04-26 DePuy Synthes Products, Inc. Endoscopic delivery of red/NIR light to the subventricular zone
US10561857B2 (en) 2008-03-03 2020-02-18 DePuy Synthes Products, Inc. Method of treating traumatic brain injury with red/NIR light
US10206784B2 (en) 2008-03-26 2019-02-19 DePuy Synthes Products, Inc. Posterior intervertebral disc inserter and expansion techniques
US9687354B2 (en) 2008-03-26 2017-06-27 DePuy Synthes Products, Inc. Posterior intervertebral disc inserter and expansion techniques
US20090325963A1 (en) * 2008-06-27 2009-12-31 Sean Lilienfeld Iontophoretic Delivery of Curcumin and Curcumin Analogs for the Treatment of Alzheimer's Disease
US8288444B2 (en) 2008-06-27 2012-10-16 Codman & Shurtleff, Inc. Iontophoretic delivery of curcumin and curcumin analogs for the treatment of Alzheimer's disease
US7745670B2 (en) 2008-06-27 2010-06-29 Codman & Shurtleff, Inc. Curcumin-Resveratrol hybrid molecule
US7985776B2 (en) 2008-06-27 2011-07-26 Codman & Shurtleff, Inc. Iontophoretic delivery of curcumin and curcumin analogs for the treatment of Alzheimer's Disease
US20100021527A1 (en) * 2008-07-25 2010-01-28 Chunlin Yang Collagen-related peptides and uses thereof and hemostatic foam substrates
WO2010042049A1 (en) 2008-10-10 2010-04-15 Milux Holding S.A. Composition, method and device for stabilizing implanted hydraulic devices
US20100190978A1 (en) * 2009-01-26 2010-07-29 Dimauro Thomas M Methylene blue - curcumin analog for the treatment of alzheimer's disease
US8609652B2 (en) 2009-01-26 2013-12-17 DePuy Synthes Products, LLC Method of administering a methylene blue-curcumin analog for the treatment of alzheimer's disease
US7906643B2 (en) 2009-01-26 2011-03-15 Codman & Shurtleff, Inc. Methylene blue-curcumin analog for the treatment of Alzheimer's Disease
US20110130392A1 (en) * 2009-01-26 2011-06-02 Dimauro Thomas M Method of Administering a Methylene Blue - Curcumin Analog for the Treatment of Alzheimer's Disease
US7723515B1 (en) 2009-01-26 2010-05-25 Codman & Shurtleff, Inc. Methylene blue—curcumin analog for the treatment of alzheimer's disease
US20100286585A1 (en) * 2009-01-26 2010-11-11 Codman & Shurtleff, Inc. Shunt Delivery of Curcumin
WO2010088469A2 (en) 2009-01-30 2010-08-05 Ethicon, Inc. Collagen-related peptides and uses thereof and hemostatic foam substrates
US20100198316A1 (en) * 2009-02-04 2010-08-05 Richard Toselli Intracranial Red Light Treatment Device For Chronic Pain
US10624758B2 (en) 2009-03-30 2020-04-21 DePuy Synthes Products, Inc. Zero profile spinal fusion cage
US9526620B2 (en) 2009-03-30 2016-12-27 DePuy Synthes Products, Inc. Zero profile spinal fusion cage
US11612491B2 (en) 2009-03-30 2023-03-28 DePuy Synthes Products, Inc. Zero profile spinal fusion cage
US9592129B2 (en) 2009-03-30 2017-03-14 DePuy Synthes Products, Inc. Zero profile spinal fusion cage
EP3831345A1 (en) 2009-07-10 2021-06-09 Implantica Patent Ltd. Hip joint device, system and method
EP3087955A1 (en) 2009-07-10 2016-11-02 Kirk Promotion LTD. Hip joint device
US20110066244A1 (en) * 2009-09-11 2011-03-17 William Frasier Minimally Invasive Intervertebral Staple Distraction Devices
US8403988B2 (en) 2009-09-11 2013-03-26 Depuy Spine, Inc. Minimally invasive intervertebral staple distraction devices
US8685097B2 (en) 2009-09-11 2014-04-01 DePuy Sunthes Products, LLC. Minimally invasive intervertebral staple distraction devices
US9216093B2 (en) 2009-09-11 2015-12-22 DePuy Synthes Products, Inc. Minimally invasive intervertebral staple distraction devices
US9744054B2 (en) 2009-09-11 2017-08-29 DePuy Synthes Products, Inc. Minimally invasive intervertebral staple distraction devices
US20110066192A1 (en) * 2009-09-15 2011-03-17 William Frasier Expandable Ring Intervertebral Fusion Device
US9615933B2 (en) 2009-09-15 2017-04-11 DePuy Synthes Products, Inc. Expandable ring intervertebral fusion device
US10792166B2 (en) 2009-11-05 2020-10-06 DePuy Synthes Products, Inc. Self-pivoting spinal implant and associated instrumentation
US10195049B2 (en) 2009-11-05 2019-02-05 DePuy Synthes Products, Inc. Self-pivoting spinal implant and associated instrumentation
US11712349B2 (en) 2009-11-05 2023-08-01 DePuy Synthes Products, Inc. Self-pivoting spinal implant and associated instrumentation
US9931224B2 (en) 2009-11-05 2018-04-03 DePuy Synthes Products, Inc. Self-pivoting spinal implant and associated instrumentation
WO2011061295A1 (en) 2009-11-19 2011-05-26 Blue Medical Devices Bv Narrow profile composition-releasing expandable medical balloon catheter
US10500062B2 (en) 2009-12-10 2019-12-10 DePuy Synthes Products, Inc. Bellows-like expandable interbody fusion cage
US11607321B2 (en) 2009-12-10 2023-03-21 DePuy Synthes Products, Inc. Bellows-like expandable interbody fusion cage
US9282979B2 (en) 2010-06-24 2016-03-15 DePuy Synthes Products, Inc. Instruments and methods for non-parallel disc space preparation
US9801640B2 (en) 2010-06-24 2017-10-31 DePuy Synthes Products, Inc. Lateral spondylolisthesis reduction cage
US9801639B2 (en) 2010-06-24 2017-10-31 DePuy Synthes Products, Inc. Lateral spondylolisthesis reduction cage
US9763678B2 (en) 2010-06-24 2017-09-19 DePuy Synthes Products, Inc. Multi-segment lateral cage adapted to flex substantially in the coronal plane
US10405989B2 (en) 2010-06-24 2019-09-10 DePuy Synthes Products, Inc. Lateral spondylolisthesis reduction cage
US9592063B2 (en) 2010-06-24 2017-03-14 DePuy Synthes Products, Inc. Universal trial for lateral cages
US11911287B2 (en) 2010-06-24 2024-02-27 DePuy Synthes Products, Inc. Lateral spondylolisthesis reduction cage
US11872139B2 (en) 2010-06-24 2024-01-16 DePuy Synthes Products, Inc. Enhanced cage insertion assembly
US9907560B2 (en) 2010-06-24 2018-03-06 DePuy Synthes Products, Inc. Flexible vertebral body shavers
US10646350B2 (en) 2010-06-24 2020-05-12 DePuy Synthes Products, Inc. Multi-segment lateral cages adapted to flex substantially in the coronal plane
US10588754B2 (en) 2010-06-24 2020-03-17 DePuy Snythes Products, Inc. Lateral spondylolisthesis reduction cage and instruments and methods for non-parallel disc space preparation
US8845733B2 (en) 2010-06-24 2014-09-30 DePuy Synthes Products, LLC Lateral spondylolisthesis reduction cage
US10449057B2 (en) 2010-06-24 2019-10-22 DePuy Synthes Products, Inc. Lateral spondylolisthesis reduction cage
US8435264B2 (en) 2010-08-30 2013-05-07 Depuy Mitek, Llc Knotless suture anchor and driver
US9775605B2 (en) 2010-08-30 2017-10-03 Depuy Mitek, Llc Knotless suture anchor with unthreaded nose
EP2422712A2 (en) 2010-08-30 2012-02-29 DePuy Mitek, Inc. Knotless suture anchor
EP2422714A2 (en) 2010-08-30 2012-02-29 DePuy Mitek, Inc. Anchor driver with suture clutch
US9370351B2 (en) 2010-08-30 2016-06-21 Depuy Mitek, Llc Anchor driver with suture clutch
US9717492B2 (en) 2010-08-30 2017-08-01 Depuy Mitek, Llc Anchor driver with suture clutch
EP2422713A2 (en) 2010-08-30 2012-02-29 DePuy Mitek, Inc. Knotless suture anchor and driver
US9364211B2 (en) 2010-08-30 2016-06-14 Depuy Mitek, Llc Knotless suture anchor
US8469998B2 (en) 2010-08-30 2013-06-25 Depuy Mitek, Llc Knotless suture anchor
EP2422711A2 (en) 2010-08-30 2012-02-29 DePuy Mitek, Inc. Knotless suture anchor
EP2422715A2 (en) 2010-08-30 2012-02-29 DePuy Mitek, Inc. Suture anchor and threader
US10660634B2 (en) 2010-08-30 2020-05-26 DePuy Synthes Products, Inc. Knotless suture anchor and driver
WO2012030754A1 (en) 2010-08-30 2012-03-08 Depuy Mitek, Inc. Knotless suture anchor with unthreaded nose
US8460340B2 (en) 2010-08-30 2013-06-11 Depuy Mitek, Llc Knotless suture anchor
US10182809B2 (en) 2010-08-30 2019-01-22 Depuy Mitek, Llc Knotless suture anchor
US11344289B2 (en) 2010-08-30 2022-05-31 DePuy Synthes Products, Inc. Knotless suture anchor and driver
US11497487B2 (en) 2010-08-30 2022-11-15 DePuy Synthes Products, Inc. Knotless suture anchor with unthreaded nose
US11464506B2 (en) 2010-08-30 2022-10-11 DePuy Synthes Products, Inc. Knotless suture anchor
US10595858B2 (en) 2010-08-30 2020-03-24 DePuy Synthes Products, Inc. Knotless suture anchor with unthreaded nose
US8679159B2 (en) 2010-08-30 2014-03-25 Depuy Mitek, Llc Anchor driver with suture clutch
US9265496B2 (en) 2010-08-30 2016-02-23 Depuy Mitek, Llc Knotless suture anchor and driver
US11529241B2 (en) 2010-09-23 2022-12-20 DePuy Synthes Products, Inc. Fusion cage with in-line single piece fixation
US11382768B2 (en) 2010-09-23 2022-07-12 DePuy Synthes Products, Inc. Implant inserter having a laterally-extending dovetail engagement feature
US10335289B2 (en) 2010-09-23 2019-07-02 DePuy Synthes Products, Inc. Stand alone intervertebral fusion device
US10369015B2 (en) 2010-09-23 2019-08-06 DePuy Synthes Products, Inc. Implant inserter having a laterally-extending dovetail engagement feature
US11678996B2 (en) 2010-09-23 2023-06-20 DePuy Synthes Products, Inc. Stand alone intervertebral fusion device
US11452607B2 (en) 2010-10-11 2022-09-27 DePuy Synthes Products, Inc. Expandable interspinous process spacer implant
US9179908B2 (en) 2010-11-23 2015-11-10 Medos International Sàrl Surgical filament snare assemblies
US10292695B2 (en) 2010-11-23 2019-05-21 Medos International Sàrl Surgical filament snare assemblies
US10912549B2 (en) 2010-11-23 2021-02-09 Medos International Sàrl Surgical filament snare assemblies
US9198653B2 (en) 2010-11-23 2015-12-01 Medos International Sàrl Surgical filament snare assemblies
US8821544B2 (en) 2010-11-23 2014-09-02 Depuy Mitek, Llc Surgical filament snare assemblies
US11039827B2 (en) 2010-11-23 2021-06-22 Medos International Sàrl Surgical filament snare assemblies
US9345468B2 (en) 2010-11-23 2016-05-24 Medos International Sárl Surgical filament snare assemblies
US9532778B2 (en) 2010-11-23 2017-01-03 Medos International Sàrl Surgical filament snare assemblies
US9895145B2 (en) 2010-11-23 2018-02-20 Medos International Sàrl Surgical filament snare assemblies
US8814905B2 (en) 2010-11-23 2014-08-26 Depuy Mitek, Llc Surgical filament snare assemblies
US8821545B2 (en) 2010-11-23 2014-09-02 Depuy Mitek, Llc Surgical filament snare assemblies
US9095331B2 (en) 2010-12-23 2015-08-04 Medos International Sàrl Adjustable anchor systems and methods
WO2012088496A2 (en) 2010-12-23 2012-06-28 Depuy Mitek, Inc. Adjustable anchor systems and methods
US9833229B2 (en) 2010-12-23 2017-12-05 Medos International Sàrl Adjustable anchor systems and methods
US10835231B2 (en) 2010-12-23 2020-11-17 Medos International Sàrl Adjustable anchor systems and methods
US8974495B2 (en) 2010-12-23 2015-03-10 Medos International Sàrl Adjustable anchor systems and methods
US8821543B2 (en) 2010-12-23 2014-09-02 Depuy Mitek, Llc Adjustable anchor systems and methods
US11369490B2 (en) 2011-03-22 2022-06-28 DePuy Synthes Products, Inc. Universal trial for lateral cages
US9248028B2 (en) 2011-09-16 2016-02-02 DePuy Synthes Products, Inc. Removable, bone-securing cover plate for intervertebral fusion cage
US10813773B2 (en) 2011-09-16 2020-10-27 DePuy Synthes Products, Inc. Removable, bone-securing cover plate for intervertebral fusion cage
US10159582B2 (en) 2011-09-16 2018-12-25 DePuy Synthes Products, Inc. Removable, bone-securing cover plate for intervertebral fusion cage
US8535350B2 (en) 2011-09-28 2013-09-17 Depuy Mitek, Llc Knotless suture anchor
US10045771B2 (en) 2011-09-28 2018-08-14 Medos International Sarl Knotless suture anchor
EP2574283A1 (en) 2011-09-28 2013-04-03 DePuy Mitek, Inc. Knotless suture anchor
EP2574284A1 (en) 2011-09-30 2013-04-03 DePuy Mitek, Inc. Knotless suture anchor
US9226764B2 (en) 2012-03-06 2016-01-05 DePuy Synthes Products, Inc. Conformable soft tissue removal instruments
US10327915B2 (en) 2012-03-06 2019-06-25 DePuy Synthes Products, Inc. Nubbed plate
US9872781B2 (en) 2012-03-06 2018-01-23 DePuy Synthes Products, Inc. Nubbed plate
US11844702B2 (en) 2012-03-06 2023-12-19 DePuy Synthes Products, Inc. Nubbed plate
US11071634B2 (en) 2012-03-06 2021-07-27 DePuy Synthes Products, Inc. Nubbed plate
US9668877B2 (en) 2012-03-06 2017-06-06 DePuy Synthes Products, Inc. Nubbed plate
US9662225B2 (en) 2012-03-06 2017-05-30 DePuy Synthes Products, Inc. Nubbed plate
US9872678B2 (en) 2012-03-30 2018-01-23 Medos International Sarl Surgical filament assemblies
US8790370B2 (en) 2012-03-30 2014-07-29 Depuy Mitek, Llc Surgical filament assemblies
US11771414B2 (en) 2012-03-30 2023-10-03 Medos International Sarl Surgical filament assemblies
US10751041B2 (en) 2012-03-30 2020-08-25 Medos International Sarl Surgical filament assemblies
US11272915B2 (en) 2012-05-07 2022-03-15 Medos International Sarl Systems, devices, and methods for securing tissue using snare assemblies and soft anchors
US10271833B2 (en) 2012-05-07 2019-04-30 Medos International Sàrl Systems, devices, and methods for securing tissue using snare assemblies and soft anchors
US10524777B2 (en) 2012-05-07 2020-01-07 Medos International Sàrl Systems, devices, and methods for securing tissue
US8894684B2 (en) 2012-05-07 2014-11-25 Medos International Sàrl Systems, devices, and methods for securing tissue using a suture having one or more protrusions
US9034013B2 (en) 2012-05-07 2015-05-19 Medos International Sàrl Systems, devices, and methods for securing tissue using a suture having one or more protrusions
US9060763B2 (en) 2012-05-07 2015-06-23 Medos International Sàrl Systems, devices, and methods for securing tissue
US9757116B2 (en) 2012-05-07 2017-09-12 Medos International Sárl Systems, devices, and methods for securing tissue
US9795373B2 (en) 2012-05-07 2017-10-24 Medos International Sàrl Systems, devices, and methods for securing tissue using a suture having one or more protrusions
US9060764B2 (en) 2012-05-07 2015-06-23 Medos International Sàrl Systems, devices, and methods for securing tissue
US11564676B2 (en) 2012-05-07 2023-01-31 Medos International Sarl Systems, devices, and methods for securing tissue
US9345567B2 (en) 2012-05-07 2016-05-24 Medos International Sàrl Systems, devices, and methods for securing tissue using snare assemblies and soft anchors
US10695047B2 (en) 2012-09-20 2020-06-30 Medos International Sarl Systems, devices, and methods for securing tissue using hard anchors
US9763655B2 (en) 2012-09-20 2017-09-19 Medos International Sarl Systems, devices, and methods for securing tissue using hard anchors
US11672523B2 (en) 2012-09-20 2023-06-13 Medos International Sarl Systems, devices, and methods for securing tissue using hard anchors
US11497616B2 (en) 2012-11-09 2022-11-15 DePuy Synthes Products, Inc. Interbody device with opening to allow packing graft and other biologics
US10182921B2 (en) 2012-11-09 2019-01-22 DePuy Synthes Products, Inc. Interbody device with opening to allow packing graft and other biologics
US10022245B2 (en) 2012-12-17 2018-07-17 DePuy Synthes Products, Inc. Polyaxial articulating instrument
US10258321B2 (en) 2012-12-27 2019-04-16 Medos International Sàrl Surgical constructs and methods for securing tissue
US9192373B2 (en) 2012-12-27 2015-11-24 Medos International Sàrl Surgical constructs and methods for securing tissue
US11369361B2 (en) 2012-12-27 2022-06-28 Medos International Sarl Surgical constructs and methods for securing tissue
US9271716B2 (en) 2012-12-27 2016-03-01 Medos International Sàrl Surgical constructs and methods for securing tissue
US11850164B2 (en) 2013-03-07 2023-12-26 DePuy Synthes Products, Inc. Intervertebral implant
US10279074B2 (en) 2013-03-14 2019-05-07 Ethicon, Inc. Implantable device having a random orientation of a non-absorbable filament
US9352071B2 (en) 2013-03-14 2016-05-31 Ethicon, Inc. Method of forming an implantable device
US10123862B2 (en) 2013-03-14 2018-11-13 Ethicon, Inc. Randomly uniform three dimensional tissue scaffold of absorbable and non-absorbable materials
US11672522B2 (en) 2013-03-15 2023-06-13 Medos International Sarl Surgical constructs with collapsing suture loop and methods for securing tissue
US10631848B2 (en) 2013-03-15 2020-04-28 Medos International Sàrl Surgical constructs with collapsing suture loop and methods for securing tissue
US9737293B2 (en) 2013-03-15 2017-08-22 Medos International Sàrl Surgical constructs with collapsing suture loop and methods for securing tissue
EP2898856A2 (en) 2013-07-18 2015-07-29 Medos International Sarl Devices for positioning and securing ligament grafts
US10463471B2 (en) 2013-07-18 2019-11-05 Medos International Sarl Methods and devices for positioning and securing ligament grafts
CN110914335A (en) * 2017-05-18 2020-03-24 阿凡田知识中心有限公司 Polyester copolymer
US10940016B2 (en) 2017-07-05 2021-03-09 Medos International Sarl Expandable intervertebral fusion cage
US10966843B2 (en) 2017-07-18 2021-04-06 DePuy Synthes Products, Inc. Implant inserters and related methods
US11690734B2 (en) 2017-08-14 2023-07-04 DePuy Synthes Products, Inc. Intervertebral implant inserters and related methods
US11045331B2 (en) 2017-08-14 2021-06-29 DePuy Synthes Products, Inc. Intervertebral implant inserters and related methods
WO2020106144A1 (en) * 2018-11-22 2020-05-28 Avantium Knowledge Centre B.V. Process for the production of one or more polyester copolymers, method for the preparation of one or more oligomers, oligomer composition and polyester copolymer
US11806245B2 (en) 2020-03-06 2023-11-07 Eit Emerging Implant Technologies Gmbh Expandable intervertebral implant
US11850160B2 (en) 2021-03-26 2023-12-26 Medos International Sarl Expandable lordotic intervertebral fusion cage

Similar Documents

Publication Publication Date Title
US4208511A (en) Isomorphic copolyoxalates and sutures thereof
US4141087A (en) Isomorphic copolyoxalates and sutures thereof
US4140678A (en) Synthetic absorbable surgical devices of poly(alkylene oxalates)
US4205399A (en) Synthetic absorbable surgical devices of poly(alkylene oxalates)
EP0086613B1 (en) Copolymers of p-dioxanone and 2,5-morpholinediones and surgical devices formed therefrom having accelerated absorption characteristics
US4226243A (en) Surgical devices of polyesteramides derived from bis-oxamidodiols and dicarboxylic acids
US4209607A (en) Polyesteramides derived from bis-oxamidodiols and dicarboxylic acids
EP0072211B1 (en) Radiation sterilizable absorbable polymeric materials and methods for manufacturing the same
EP0707044B1 (en) Absorbable polymer blends
US5047048A (en) Crystalline copolymers of p-dioxanone and ε-caprolactone
US4643734A (en) Lactide/caprolactone polymer, method of making the same, composites thereof, and prostheses produced therefrom
US4605730A (en) Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same
US4700704A (en) Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same
CA1124943A (en) Synthetic absorbable surgical devices of poly-dioxanone
EP0176895B1 (en) Absorbable crystalline alkylene malonate copolyesters and surgical devices therefrom
US5633343A (en) High strength, fast absorbing, melt processable, gycolide-rich, poly(glycolide-co-p-dioxanone) copolymers
US4546152A (en) Poly(p-dioxanone) polymers having improved radiation resistance
JPH0696633B2 (en) Process for producing copolymer of glycolide and ε-caprolactone
EP0672699A2 (en) Copolymers of 1,4-dioxepan-2-one and 1,5,8,12-tetraoxacyclotetradecane-7-14-dione
US4435590A (en) Radiation sterilizable absorbable polymeric materials and methods for manufacturing the same
US4649921A (en) Poly(p-dioxanone) polymers having improved radiation resistance
CA1120640A (en) Isomorphic copolyoxalates and sutures thereof
GB1590261A (en) Isomorphic copolyoxalates and sutures thereof
Shalaby Polyaxial Crystalline Fiber-Forming Copolyester